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Abstract of the Dissertation  
 
Background: Peripheral artery disease (PAD) is a progressive disease characterized by 
its impact on physical mobility, and a high rate of vascular comorbidities and events. 
Despite its inclusion in the same grouping of conditions as cardiovascular (CVD) and 
cerebrovascular diseases, PAD garners much less attention, both in a clinical setting 
and in research. There is a significant body of research on the roles of nutrition and 
lifestyle in CVD and stroke etiology, yet the equivalent data for PAD is sparse. The 
impact of nutrition and related factors on PAD is poorly understood, and in need of 
expansive clarification. 
Methods: We conducted a literature review of all available research on nutrition and 
body composition in PAD, and used our assessments to design a cross-sectional study 
of these variables in a sample of PAD patients. We created a conceptual model of how 
nutrition-related variables may be associated with various aspects of PAD severity, and 
examined these associations within recruited participants. 
Results: Participants diets’ were characterized by relatively high intakes of fat, sugar and 
sodium, as well as by low or inadequate intakes of crucial micronutrients. Several dietary 
factors were found to be significantly associated with more severe physical or 
psychosocial PAD symptoms. The majority of participants were also overweight or 
obese, and total body weight and abdominal obesity were associated with worse scores 
on tests of PAD severity. Additionally, we encountered several key obstacles to 
identifying and recruiting patients for this study. 
Conclusions: Although our sample size was relatively small, there is evidence to suggest 
that there are nutrition-related factors that are associated with the severity of PAD 
patients’ symptoms and overall quality of life. Recruitment methods are in need of 
revision to obtain larger, more statistically powered samples, and we have outlined 
potential approaches for doing so. Lastly, this study establishes a precedent for future 
studies to implement interventions in PAD patients using already-established vascular 
guidelines for nutrition. 
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General Introduction 
Definition of Peripheral Artery Disease 
 Peripheral Artery Disease (PAD), also known as Peripheral Vascular Disease or 
Peripheral Arterial Occlusive Disease, is not a single, narrowly delineated condition, but 
rather is a general term for a range of noncoronary arterial syndromes. Broadly, PAD 
can be used to describe a variety of arteriosclerotic processes that lead to: One, the 
deposition of fatty plaques on arterial walls that progress to atheroma formation and 
thrombosis or thrombotic embolism; or two, a degradation of the structural integrity of 
arterial walls that results in thinning or thickening of the wall (dilation or dysplasia) and 
aneurysm formation1. These syndromes affect arteries in limbs and visceral organs, 
particularly the abdominal aorta, lower extremity arteries, renal arteries and mesenteric 
arteries. While other peripheral arterial beds may also be affected by similar syndromes 
(e.g. the arteries in the upper extremities or the vertebral column1), there is little research 
in these areas, and clinical guidelines focus primarily on visceral organs and the lower 
limbs. 
 The arteriosclerosis that defines PAD can be viewed as a systemic process, one 
that can promote or aggravate arterial disease in the brain and heart. People with PAD 
often have a concurrent history of cardiovascular disease (CVD)2,3 and have a 
significantly increased risk of experiencing CVD events, including myocardial infarction, 
stroke and death. Depending on the location of a stenosis or aneurysm, other outcomes 
may include ischemia in the mesenteric artery bed, ischemic renal failure, rupture of an 
aneurysm or tissue necrosis and limb loss. 
Risk Factors, Signs and Symptoms 
Many risk factors for PAD are also risk factors for CVD, including, but not limited 
to dyslipidemia, obesity, diabetes mellitus, hypertension, a family history of CVD or PAD 
and smoking4,5. Smoking is a particularly significant risk factor – the risk of developing 
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lower extremity PAD has a dose-dependent association with daily frequency and years 
of smoking6-9. Approximately 80% of PAD patients are current or former smokers10,11, 
although this percentage may underestimate the total impact of cigarette use by not 
accounting for nonsmoking patients who cohabitate with smoker spouses or relatives. 
 The location of an aneurysm or stenosis can in large part dictate patients’ 
accompanying clinical signs and symptoms. For example, patients with acute ischemia 
in a mesenteric artery will likely report abdominal pain, while a patient with PAD in a 
renal artery (i.e. renal artery disease, or RAS), may be asymptomatic and be diagnosed 
only when a clinician measures the presence of refractory hypertension1,12. 
Nevertheless, PAD can be present in different locations within the body simultaneously. 
Lower extremity PAD is the more common form, and involves pain, cramping and 
discomfort in the legs, specifically calves, thighs, or buttocks. For many symptomatic 
PAD patients, their primary experience is of intermittent claudication (IC), in which 
physical exertion brings on pain or cramping, and is relieved by rest13.  Another 
common, more severe set of symptoms is critical limb ischemia (CLI, also known as 
acute limb ischemia), in which a rapid-onset lack of blood flow in a leg causes acute 
pain, tingling or numbness, and is not alleviated by rest13.  
 Lastly, and perhaps more critically, a large proportion of people with PAD are 
asymptomatic prior to an ischemic event. Estimates vary, but at any given time up to half 
of people with PAD do not have symptoms14. Also, it is difficult assess what proportion of 
the asymptomatic truly do not experience lower extremity pain or discomfort - PAD is a 
disease of aging like CVD15, and many people ascribe leg symptoms to old age or other 
coexistent conditions, thereby categorizing themselves as “asymptomatic”1. 
PAD Prevalence and Disease Burden 
 Given the difficulty of assessing PAD prevalence accurately, published estimates 
vary. Within the U.S., available data suggest that between 4 and 14% of people aged 50 
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to 80 years old have one or more PAD syndromes16. Additionally, approximately 70% of 
patients with lower extremity PAD and/or CVD concurrently suffer from renal artery 
stenosis (RAS)17, while up to 85% of patients with aneurysms in their lower extremities 
simultaneously have abdominal aneurysms18,19.  PAD in mesenteric arteries is less 
common (both acute and chronic intestinal ischemia are relatively rare1,12), but without 
treatment is almost always fatal1.  PAD tends to affect men and women equally, though 
women are significantly more likely to develop intestinal ischemia1. When stratified by 
race and ethnicity, Latinos have a higher prevalence of PAD than Caucasians, but have 
lower rates than African Americans, who have the highest PAD rates, along with a 
significantly greater risk of experiencing poor disease outcomes20-22 (see Manuscript 1, 
“Ethnic Disparities” section). The high prevalence of PAD and the interrelated nature of 
its various syndromes and comorbidities contribute to a significant disease burden. As of 
2008, annual health care costs for PAD exceeded 21 billion dollars, surpassing costs of 
CVD treatment by approximately 23%23.  
Current PAD Treatment Guidelines 
In 2006, the Committee to Develop Guidelines for Peripheral Arterial Disease first 
published evidence-based clinical recommendations for PAD screening and treatment1, 
with a more recent update in 201112. These recommendations comprise the first major 
published effort to assess comprehensively available evidence on PAD treatments and 
interventions. The guide emphasizes clinicians’ general consensus that PAD has 
historically received considerably less attention than CVD, and that the substantial 
health and cost burden merit concern4,24.  
 Clinicians’ approaches to treating PAD are contingent on a variety of factors, 
including the severity of patients’ symptoms, the location and size of a stenosis or 
aneurysm, the relative health of the surrounding vascular anatomy, and an assessment 
of the likelihood that a given intervention will yield lasting results. Medications frequently 
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comprise the first line of intervention and are tailored to specific goals; for example, to 
decrease the risk of a CVD event, clinicians may prescribe singly or in combination lipid-
lowering medications, anti-hypertensives, glucose control drugs for diabetics or anti-
thrombotic drugs. For patients reporting IC or CLI, additional medications may also 
include analgesics, platelet inhibitors and drugs that inhibit vascular cell adhesion, while 
RAS treatment may further incorporate medications targeted towards inhibiting 
angiotensin receptors and renal calcium channels1,12. 
  Revascularization is recommended for patients in various stages of disease, 
including when stenosis has completely occluded blood flow, when an aneurysm is at 
imminent risk of rupture (or has already ruptured), when tissue is in danger of 
necrotizing, or when a patient finds that discomfort and hampered physical mobility 
become intolerable. In these circumstances, guidelines again delineate evidence-based 
approaches to treatment. Procedures are generally categorized as endovascular or 
operative. Endovascular treatments may for instance be catheter-based thrombolysis of 
an occlusion or balloon angioplasty stent placement. More invasive procedures are used 
when endovascular approaches are not viable – a patient may have other serious 
concurrent health conditions that limit the effectiveness of percutaneous interventions or 
perhaps the patient’s vasculature is not sufficiently stable or healthy to sustain such a 
procedure. In such circumstances, surgical interventions may include bypass grafting, 
resection of necrotic tissue, or limb amputation1,12. 
 Regardless of treatment approach, a clinician’s primary goals center on 
improving quality of life and preserving the viability of limbs and organs, while attempting 
to reduce the risk of ischemic events. Nevertheless, even as these approaches can be 
highly effective, there remains much that is unknown about non-pharmacological and 
non-operative ways of treating, or perhaps even preventing PAD. Such approaches may 
be comprised of physical activity interventions, nutrition programs, or other lifestyle-
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based measures. There is a body of research on physical activity25-27 that has shown the 
potential for exercise programs to improve patients’ physical function. While this area 
warrants further exploration, there remains a persistent gap in PAD research in regard to 
nutrition. Given the validated importance of nutrition in CVD treatment28, it may be an 
important area of research that has the potential to influence clinical practice. This 
dissertation is an attempt to begin to bridge this knowledge gap, and in doing so, expand 
the body of research on the role nutrition may play in clinical PAD care. 
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Manuscript 1:  
The role of nutrition and body composition in peripheral arterial disease. 
Note: This manuscript first appeared in Nature Reviews Cardiology, 2012 November; 
9(11):634-43, PMID: 22922595, doi: 10.1038/nrcardio.2012.117. 
 
Abstract 
Objectives. To provide an evidence-based review regarding the influences of nutrition 
and body composition on atherosclerotic lower extremity peripheral arterial disease 
(PAD). 
Design. Critical review. 
Methods. Review of the published literature (1990 to present via PubMed) examining 
associations between nutrition, body composition and PAD.  Seventy studies were 
selected, and methodologic and data quality were critically assessed. 
Results. There is strong evidence that decreased intake of folate and vitamin D is 
associated with greater risk of PAD and worsened walking impairment and that 
abdominal obesity is associated with greater risk of PAD and greater concentrations of 
pro-inflammatory biomarkers. There is moderate evidence that increased intakes of 
niacin and insoluble fiber are associated with improved serum lipids and decreased 
thrombogenic biomarkers and that homozygosity for the MTHFR T-allele negatively 
impacts homocysteine metabolism and thus promotes the progression of PAD severity. 
There is no evidence that vitamins A, C, E, B6 or B12 play a significant role in PAD, or 
that essential fatty acid supplementation improves clinical outcomes. 
Conclusions. There is a relative paucity of research on nutrition and body composition 
in relation to PAD, as compared to other cardiovascular diseases, suggesting that further 
research is essential to elucidate this relationship.  
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Introduction  
Atherosclerosis remains the number one cause of mortality in the United 
States14, and is recognized as a set of distinct clinical syndromes (coronary heart 
disease, ischemic stroke, and PAD) that affects both individuals and communities. While 
the coronary and stroke syndromes are better known as traditional components of the 
cardiovascular disease (CVD) burden, peripheral artery disease (PAD) is equally 
common and is associated with an equal or higher risk of morbid and mortal events and 
a higher health economic cost23,29. PAD is defined as atherosclerosis of the abdominal 
aorta and arteries outside the heart, and the term is most commonly used to describe 
arterial disease of the infrarenal aorta and the lower extremities30. It is estimated that 
PAD affects 4 to 14% of the U.S. population from ages 50 to 80 years16. Cardiovascular 
ischemic events (e.g., heart attack and stroke) are frequent outcomes, and patients 
experience a significantly increased risk of leg amputation and premature mortality4,16. 
 Like other forms of CVD, PAD results from one or more risk factors including 
smoking, diabetes mellitus, hypertension, obesity and dyslipidemia, as well as a family 
history of CVD or PAD 4,5. Figure 1 presents a model that depicts how these genetic and 
modifiable lifestyle factors may interact to contribute to PAD risk. Unlike other CVD, 
however, the body of research on PAD is less robust.  Recent data document that the 
disease is persistently underdiagnosed and undertreated, both in terms of lifestyle 
interventions and pharmacological therapies4,24,31.  
A series of potential explanations may underlie the past knowledge gaps and 
lower investigational priority of PAD compared to other CVD. For example, PAD is 
frequently asymptomatic prior to causing a recognized ischemic event. It is estimated 
that only 25 to 50% of people with PAD exhibit difficulty walking and/or leg symptoms.  
Standards of clinical care present another barrier, as the majority of care providers either 
lack training in measuring ankle-brachial indices (ABI) (the standard PAD diagnostic 
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tool), or feel that time constraints limit their ability to conduct these simple tests32. 
Overall, there is a profound lack of public awareness about PAD4,24, and this low 
awareness, high prevalence and cost have led to the creation of new evidence-based 
PAD clinical care guidelines22. 
 The purpose of this critical review is to summarize the current evidence base 
regarding the role of nutritional and anthropometric factors on PAD incidence and risk, to 
assess the strength of the evidence for these associations, and to outline concepts that 
may help future investigators in the design of nutrition-focused PAD clinical research. 
We have approached this review using the criteria presented in Figure 2 to rate the 
quality of each study. 
Results of Critical Review 
 We identified eleven factors relating to nutrition or body composition that have 
been investigated in the context of PAD incidence.  Current evidence for an association 
between each factor and PAD is summarized in Table 133-103, including key causality 
hypotheses, the proposed biological mechanism for each association, the number and 
types of studies published, results, and potential avenues of future investigation.  
Micronutrients 
B vitamins: folate, B6, B12 and niacin 
 Currently, it is thought that inadequate dietary intake and/or absorption of B 
vitamins may influence PAD etiology via homocysteine (Hcy) regulation. As a crucial 
intermediary in amino acid synthesis (from dietary methionine), Hcy cycles between 
conversion to the cysteine precursor cystathionine, and remethylation back to 
methionine104. While the conversion to cystathionine is vitamin B6-dependent, 
remethylation requires folate and vitamin B12 as cofactors
104. Evidence suggests that a 
folate deficiency contributes to a decreased ability to maintain the cycle’s homeostasis. 
A build-up of unmetabolized serum Hcy may lead to potentially toxic concentrations, and 
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has been found to contribute to endothelial dysfunction, vasoconstriction and 
inflammation105,106. Nevertheless, it is unclear precisely how low folate intake or high Hcy 
concentrations promotes PAD pathogenesis. 
 Cross-sectional studies of folate intake and PAD outcomes have used a range of 
assessment methods, including self-reported food frequency questionnaires (FFQ), 24-
hour dietary recall interviews, as well as measurement of serum folate concentrations. 
These studies provided concordant data that participants with lower folate intake were at 
significantly greater risk of having PAD than those consuming greater quantities. 
Reported results ranged from a 33% increase in prevalence risk comparing lowest to 
highest intakes72, to a significantly higher prevalence of folate deficiency in PAD cases 
versus controls (6.4% versus 2.9%) . Prospective cohort study and clinical trial evidence 
is more equivocal. The sole epidemiological study83 calculated intake data from nutrition 
tables published prior to the introduction of folate fortification in 199633, thus potentially 
underestimating dietary intake, and only observed a protective association between PAD 
risk and folate among subjects taking folate-containing multi-vitamins (relative risk for 
highest intake versus lowest = 0.67). One clinical trial66 evaluated folate supplementation 
alone, while two36,42 used multi-nutrient supplements, limiting the ability to discriminate 
causal pathways. Nevertheless, Carrero et al36 observed significant improvement in 
patients’ walking distance and ABI scores (in the supplement group, a 3.5-fold increase 
in walking distance from baseline, and a 13% increase in ABI). All three clinical trials 
observed significant reductions in serum Hcy concentrations. The same case-control 
studies that evaluated folate’s association with PAD also assessed B12
35,101 and 
concluded that there is no association between B12 and either PAD prevalence or 
incidence.  
Two clinical trials performed by de Jong et al42 and Carrero et al9 included B6 in 
the multi-nutrient supplements ingested by PAD patients. Thus, while both studies 
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concluded that B6 supplementation decreases serum Hcy concentration and improved 
vascular function, the B6-specific effects cannot be determined independently of the 
other compounds included in the supplements.   
Finally, a small number of studies have assessed the association of niacin intake 
with PAD-related lipid profiles or clinical outcomes. Based on the premise that niacin is 
known to inhibit hepatic LDL cholesterol synthesis107,108 and that it may influence 
endothelial inflammatory mechanisms in PAD etiology109-111, five clinical trials37,45,54,61,85 
have been performed to assess the effect of niacin supplementation on lipid profiles or 
walking function in individuals with PAD. Three of the trials37,54,85 included niacin with 
antioxidant supplements, possibly confounding the interpretation of the outcomes. All 
trials that assessed lipids and inflammatory biomarkers observed significant changes 
(decreases in fibrinogen and prothrombin37, increases in serum HDL cholesterol45,85) 
while one trial of walking function61  observed a 37.8% increase in peak walking times 
among subjects taking niacin compared to those taking a placebo.  
Vitamin D 
 Only within the last decade have researchers begun to investigate vitamin D and 
its relationship to PAD. Low vitamin D status is associated with increased incidence of 
various cardiovascular diseases, including heart failure, myocardial infarction, and 
hypertension112-114. One mechanistic hypothesis46 posits that decreased sun exposure 
among physically impaired PAD patients leads to a decline in vitamin D synthesis, 
causing a decrease in intestinal calcium absorption.  This would be anticipated to be 
associated with greater renal calcium loss and a compensatory increase in parathyroid 
hormone (PTH) secretion to maintain serum calcium concentrations. A self-perpetuating 
cycle may begin in which hypovitaminosis D promotes hyperparathyroidism, which 
increases the risk of bone pain (osteomalacia), and further exacerbates a PAD patient’s 
immobility. Recent data also suggest that hypovitaminosis D may promote arterial 
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calcification102,115. While the precise mechanisms remain unclear, it is believed that 
vitamin D may simulate its regulatory role in bone mineralization by promoting 
osteoblast-like function in arterial smooth muscle cells102. These osteoblast-like cells 
may promote calcium deposition in arterial walls, contributing to atherosclerosis. 
To date there have been no prospective studies or clinical trials of vitamin D 
supplementation in individuals with PAD. Nevertheless, six cross-sectional and case-
control studies46,47,67,82,89,102 have concluded that vitamin D deficiency is significantly 
associated with increased odds of prevalent PAD and/or PAD severity.  NHANES data 
showed an inverse linear association between hypovitaminosis D and PAD prevalence 
(two analyses, ranging from 7.7% to 8.1% prevalence)67,82.  The most recent study by 
Zagura et al102 also measured arterial calcification in PAD cases and healthy controls, 
and observed a significant association between calcium deposits and PAD, with 6% of 
PAD patients having arterial calcification compared to less than one percent in healthy 
controls.  
Other dietary components 
Antioxidants 
 Building on previous studies of dietary antioxidants (AOX) and oxidative stress in 
CVD116-119, researchers have also begun to assess what influence AOX may have on 
similar inflammatory pathways in PAD. The majority of available research focuses on 
vitamins E, C and beta-carotene33,36,37,40,41,44,54,70,72-75,85,97,98.  Seven cross-sectional, case-
control and epidemiological studies used a range of assessment methods 
(questionnaires, 24-hour recalls, etc.) and concluded that subjects with higher dietary 
AOX intakes were at significantly lower risk of having or developing PAD compared to 
subjects with lower intakes. Odds ratios for prevalence among highest dietary AOX 
intake ranged from 0.37 to 0.84 when compared to lowest intakes33,72,73, and 
observational studies reported risk ratios for PAD incidence ranging from 0.64 to 0.89 for 
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subjects with highest AOX intake compared to lowest intake70,97. Supplementation trials, 
however, produced more ambiguous results. All eight randomized trials36,37,40,41,54,75,85,97, 
used multi-nutrient supplements which, like the B-vitamins studies, limits the ability to 
discern vitamin-specific associations. Six studies observed no changes in PAD 
symptoms or ABI measures in the patients who received supplementation compared to 
baseline.  Two trials36,97 reported highly varied results. Carrero et al’s36 trial that 
observed improvements in walking distance and ABI also included vitamin E in their 
supplements, while Tornwall et al97 noted that subjects taking only beta-carotene 
experienced a slight increase in risk of requiring vascular surgery (OR = 1.6 in 
supplemented group versus placebo group), an outcome the authors argued may have 
been the result of carotenoid uptake into arterial plaques120. 
Finally, there is a very small body of research on other compounds with anti-
oxidant activity. A recent analysis of 2003-2004 NHANES data34 assessed the 
relationship between selenium intake and PAD prevalence, and noted that participants 
with higher selenium intakes were at a lower risk of prevalent PAD (OR = 0.67 for 
highest versus lowest intakes). The same year, Hawkes et al60 published results of a 
clinical trial of selenium supplementation in healthy males. Although participants’ serum 
selenium concentrations increased significantly, the authors did not observe any 
changes in endothelial markers. A case-control study of dietary flavonoids74 observed 
that PAD cases had significantly lower flavonoid intake when compared to controls, and 
Grassi et al’s58 trial of flavonoid supplementation (derived from black tea) observed 
significant, dose-dependent increases in arterial dilation (up to 2.3%) and decreases in 
arterial stiffness (mean change in Stiffness Index = -0.71 ± 0.29 m/s) . Lastly, one 
randomized trial80 attempted to observe the effects of an L-arginine-enriched nutrition 
bar on leg pain and walking distance. After two weeks, subjects in the supplementation 
group reported significantly decreased leg pain and an average increase in pain-free 
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walking distance of 66%. When this arginine intervention was then evaluated in a larger 
prospective randomized trial, however, no benefit on claudication was observed121.  
Dietary Fiber 
 Based on previous studies of dietary fiber and cholesterol in CVD122-124, five 
cross-sectional and epidemiological PAD studies44,55,63,72,83 have examined dietary fiber. 
All studies but one63 concluded that greater intake of dietary fiber was associated with 
decreased risk of incident or prevalent PAD.  Odds ratios of PAD prevalence in subjects 
with highest fiber intake compared to lowest ranged from 0.65 to 0.8055,72. Although to 
date there have been no prospective dietary intervention trials, the evidence specifically 
suggests that cereal fiber may be associated with a decreased risk of developing PAD.   
 Donnan et al44 investigated participants in the Edinburgh Artery Study and 
delineated the impact of varying fiber sources. They concluded that higher intake of 
cereal fiber, predominantly insoluble in nature, was associated with higher ABI values. 
Among men specifically, increasing cereal fiber intake (defined as rarely, 1-3 times/week 
or 4-7 times/week) was associated with an ABI increase of 0.04 per frequency category. 
Two epidemiological studies of Health Professional Follow-up data63,83 further support 
the cereal fiber hypothesis. Hung et al63 analyzed FFQ data for fruit and vegetable intake 
and PAD incidence, while Merchant et al83 analyzed fiber intake (total, cereal-based, and 
fruit/vegetable-based). Whereas Merchant et al8 did not observe any significant 
associations between incident PAD and total fiber intake, upon separating fiber types the 
authors found a significant correlation between increased cereal fiber intake and lower 
risk of developing PAD, even after adjustment for other risk factors (CI = 0.67). Hung et 
al63 on the other hand concluded that fruit and vegetable intake taken as a whole had no 
association with incident PAD, suggesting that soluble fiber may have little impact in this 
context. 
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Fats 
 A growing body of research has also begun to examine the roles of various types 
of dietary fats in PAD etiology. Relying on associations between saturated fat intake and 
heart disease as a precedent125, cross-sectional and case-control studies have reached 
similar conclusions that people with PAD are more likely to consume high total fat55  
and/or high saturated fat39,65 diets. Other research has observed that PAD patients are 
significantly less likely to consume diets rich in polyunsaturated vegetable fats33,98, 
particularly polyunsaturated n-3 essential fatty acids (EFA)72,74. The n-3 EFA are of 
especial interest in vascular research, as it is believed they function as anti-inflammatory 
agents that counteract the reactive oxygen species associated with endothelial damage 
and atherosclerotic inflammation126,127.  
 Results of clinical trials of n-3 EFA supplementation in PAD patients have varied. 
A short, 12-week trial of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
supplementation observed significant increases in walking distance and ABI (mean 
increases of 82 meters and 0.18, respectively)78, while a two-year trial75 observed no 
changes. Leng et al75 randomized 120 subjects to receive either an EFA supplement or 
a placebo, and after two years there were no intra- or inter-group differences in physical 
function, vascular measures or serum lipid concentrations. A 2007 meta-analysis95 
analyzed data from six n-3 supplementation trials, and although the authors noted a 
moderate increase in blood viscosity among subjects taking EFA capsules, 
supplementation had no discernible net impact on PAD outcomes.  
Since the publication of this meta-analysis, a small clinical trial by Schiano et al92 
observed no improvement in PAD symptoms, either from baseline among subjects 
receiving n-3 supplements, or compared to the placebo group. In this instance, the small 
sample size (n = 16 per study arm) and short 3-month trial duration both hampered the 
ability to observe any possible changes that could take place over the long-term in a 
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larger cohort. At the time of this writing, a year-long n-3 supplementation by Leyva et al76 
is underway, with results forthcoming.  
Gene – diet interactions 
A total of eleven studies have been conducted of single nucleotide 
polymorphisms (SNPs) and their associations with PAD etiology. It is thought that certain 
SNPs can result in disordered or inefficient metabolic processes, and that these in turn 
may predispose people to a greater risk of developing PAD and other vascular diseases.  
 To date, the vast majority of research on SNPs and PAD has focused on 
MTHFR, the gene that encodes methylenetetrahydrofolate reductase (MTHFR). MTHFR 
functions as the enzymatic catalyst in remethylating homocysteine to methionine, and it 
is as crucial to regulating serum Hcy as folate and vitamin B12. The C667T mutation in 
MTHFR is believed to cause an estimated 50% reduction in MTHFR activity, possibly 
decreasing the body’s ability to regulate serum Hcy128. Approximately 10% of the human 
population is homozygous for this point mutation (genotype TT)129,130.  
 The evidence for a significant association between MTHFR mutations and PAD 
risk remains unclear. Three studies did not measure serum Hcy concentrations48,87,131, 
while the remaining studies were split between contradictory conclusions. Overall, 
MTHFR genotyping studies assessed blood samples in cohorts ranging from 5188 to 
94048 participants.  Authors’ observations did not vary by sample size. 
Six studies38,48,84,91,100,131 reported no significant differences in mutation 
prevalence between cases and controls and four38,48,84,100 of those studies reported 
similar, and nearly identical, prevalence rates between groups. Two studies87,132 
observed a higher prevalence of a T allele and/or TT genotype among PAD cases, and 
concluded that subjects with a T allele had a higher 1.18 to 3.54 risk (odds ratio) of 
prevalent PAD. While most investigations have reported no no deviations from the 
Hardy-Weinberg Equilibrium (HWE), two studies by Fowkes et al48 and Khandanpour et 
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al132 observed an under-representation of TT genotypes among controls, even while 
reaching opposing conclusions about TT homozygosity and PAD risk. Lastly, two meta-
analyses also reported contradictory findings. Zintzaras et al133 and Khandanpour et al51 
analyzed data from seven and nine studies, respectively, with four studies overlapping. 
Zintzaras et al52 concluded there was no difference in genotype distribution between 
cases and controls, whereas Khandanpour et al51 reported a statistically significant odds 
ratio of 1.99 for PAD prevalence in TT genotypes versus CC types. 
Lastly, a small number of studies have begun to examine other SNPs in a PAD 
context. Results are still preliminary, but research into prothrombin G20210A and Factor 
V Leiden genotypes69,84,94 (both co-factors involved in clotting cascades69)  has so far not 
found significant differences in genotype distributions.  
Body composition 
 Obesity is a well-established risk factor for CVD134,135, and the impact of body 
mass and body composition on incident CVD and disease progression remains an area 
of active investigation136. It is now understood that total body weight, as estimated by 
body mass index (BMI), is not an ideal predictor of overall atherosclerotic risk137-139. An 
obese person may have a normal metabolic profile with no accompanying signs of CVD, 
while an only slightly overweight person can experience severe CVD with multiple 
comorbidities134. Analyses of body composition140-144, defined by the quantity and 
visceral locations of fat tissue, have revealed that abdominal fat is a more precise 
predictor of atherosclerosis risk than shear weight141,144. It is also increasingly 
understood that abdominal adipose mass is not inert, but is a metabolically active tissue 
capable of secreting hormones that influence serum lipid concentrations, glucose and 
insulin regulation, inflammatory pathways, and endothelial function140,142,143. As a result, 
CVD research now frequently employs waist circumference (WC) singly, or with hip 
circumference (HC) as a measure of abdominal obesity145.    
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Studies of body composition and PAD have not been consistent in their 
assessment methods. Of 18 cross-sectional and prospective observational studies, 10 
assessed both BMI and abdominal obesity in their cohorts, whereas the remaining 8 
measured only BMI. Of the 10 studies that measured abdominal adiposity, the majority 
measured body circumferences, while one used DEXA body density scans53 . These 10 
studies had concordant results, for example, Makdisse79 et al reported a 59% 
prevalence of abdominal obesity among PAD patients compared to 35% among 
controls79, Planas et al86 observed an odds ratio of 1.68 of PAD prevalence in the 
abdominally obese versus healthy-weight subjects, and Golledge et al57 observed a risk 
ratio of 1.16 for CVD events or death in PAD patients with greater abdominal fat 
deposition compared to leaner participants. Of those, all but three49,77,86 also reported 
that greater total obesity (as BMI) was associated with more adverse PAD-related 
outcomes compared to leaner subjects. Of the 8 studies that only measured BMI, five 
still concluded that total obesity increased odds of adverse outcomes, including having a 
lower limb amputation50 or experiencing a more rapid decline in peak walking distance81. 
Interestingly, two of the remaining studies51,71 reported that increased BMI was 
significantly inversely associated with PAD incidence or prevalence. Galal et al51 
reported that normal-weight subjects experienced a 50% rate of overall mortality 
compared to 31% among obese subjects, and Kumakura et al71 observed an 18% 
decrease in risk of all-cause mortality among people with high BMI versus low. 
Researchers have termed this phenomenon “the obesity paradox”146, in which leaner 
body mass appears to be associated with a greater risk of atherosclerotic events. In the 
context of PAD, authors ascribe the paradox to confounding variables that are both more 
common among lean subjects, and are independent predictors of atherosclerosis. 
Specifically, leaner subjects have a higher frequency of smoking and/or chronic 
obstructive pulmonary disease (COPD), underweight status and overall malnutrition, all 
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of which can contribute to PAD risk51,71,146. In fact, Ix et al103, one of the 5 groups that 
reported a higher risk of adverse CVD events among obese PAD patients, only observed 
this association among subjects who had never smoked (HR = 1.32). For the remaining 
3 studies that reported an inverse association between PAD and obesity, two reported a 
significantly greater proportion of smokers, COPD-diagnosed, and/or underweight 
subjects in their cohorts51,71. This, in addition to their use of BMI as the sole parameter of 
obesity may explain their inverse results. Overall, the evidence suggests that when 
these factors are accounted for, higher BMI remains significantly associated with greater 
PAD prevalence. 
Other nutritional issues – ethnic and racial disparities 
 Nutrition may also be an important mediating factor in racial and ethnic 
differences in PAD prevalence. African Americans experience a significantly higher 
burden of PAD compared to their Caucasian counterparts20,21,147, and this disparity is 
only partly explained by traditional risk factors21,148,149. A recent study by Khawaja et al150 
explored possible reasons for this excess risk, and concluded that while “novel” factors, 
such as increased serum concentrations of lipoprotein(a) (associated with inflammatory 
pathways) may partially explain the disparity, African American ethnicity is still 
significantly associated with higher PAD risk. 
A possible nutritional explanation may be found in vitamin D. Evidence strongly 
suggests there is a racial disparity in vitamin D deficiencies in the United States: people 
with darker skin pigmentation, particularly African Americans, have significantly higher 
rates of deficiency compared to their Caucasian counterparts151. This may be due to 
differing ability to convert sun-derived precursor 7-dihydrocholesterol to pre-vitamin D3. 
Populations with darker skin, and therefore higher cutaneous melanin concentrations are 
less efficient in this conversion process152,153. When African Americans live in northern, 
less sunny latitudes, they are at especially high risk of developing vitamin D deficiencies. 
19 
 
Two analyses of 2001-2004 NHANES data examined racial differences in serum vitamin 
D concentrations and PAD. Kim et al67 observed that while all ethnicities with vitamin D 
deficiency are at greater risk of having a cardiovascular disease, African Americans had 
a higher prevalence of deficiency (97%) than Caucasians or Hispanics (68% and 88%, 
respetively). Reis et al’s89 analysis supported these conclusions, and after adjusting for 
all known PAD risk factors, concluded that hypovitaminosis D accounted for 
approximately one-third of excess PAD risk among African Americans.  
Key implications for future research 
 To date there are no established dietary guidelines that synthesize evidence into 
nutritional treatment recommendations for PAD patients.  To our knowledge, this is the 
first critical review of this topic. In order to delineate more precisely how diet and body 
composition may influence PAD severity and progression, it would seem prudent for 
future studies to improve on previously used methods. Evidence strongly indicates that 
abdominal obesity is significantly associated with PAD risk and, and future studies 
should confirm this observation.  Current data suggests that BMI measures alone may 
not account for all sources of obesity-related risk, and researchers should expand the 
use of DXA or other measurements to expand this body of data. A prospective clinical 
trials of weight loss interventions may be required to evaluate this causal relationship 
more precisely.   
 Future supplementation trials should also improve on previous PAD-nutrition 
knowledge limitations. Wide variations in nutrient dosages and trial durations restrict the 
ability to draw conclusions and thus establish evidence-based clinical recommendations. 
Additionally, past trials have not assessed baseline intakes and/or bodily concentrations 
of the nutrients of interest, thus overlooking key  deficiencies, and further limiting 
interpretations of results. Future investigations of genetic contributions to PAD should 
include data on pre- and post-trial nutrient concentrations and might  compare these to 
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patient genotypes. For example, as some genetic studies have shown that MTHFR 
genotype distribution can vary by PAD status, incorporating a genetic profile, along with 
Hcy measurements into a folate supplementation trial would greatly strengthen the 
validity of such a trial’s findings. For vitamin D, more attention should be paid to baseline 
status and racial and geographic influences on endogenous synthesis.    
Finally, observational studies of nutrition could also strengthen their approach by 
assessing baseline nutrient concentrations (even if only in a subset of a larger cohort), 
and validating FFQ data with 24-hour dietary recalls. While FFQs in large 
epidemiological studies yield valuable information on population-wide trends, more 
refined measures like dietary recalls could provide a more detailed body of data on 
which to base clinical trials. 
Clinical implications 
 The potential for nutritional research to inform PAD clinical practice should not be 
underestimated. Over 21 billion dollars are spent annually on PAD treatment in the 
U.S.23, with per-patient expenditures surpassing the costs of coronary artery disease by 
5 percent. Endovascular therapies, such as stents and angioplasty, are now standard 
PAD treatments29, yet they frequently require repeated interventions154, and often result 
in post-intervention  complications, both of which in turn contribute to even greater 
costs155.   
Lifestyle-oriented interventions may be most effective if individuals with PAD are 
provided “actionable knowledge” regarding the impact of overweight and obesity on their 
disease.  As for other CVD, individuals may enjoy improved health with increased 
awareness of the synergistic impact of physical activity, andt also of caloric intake and 
portion sizes as these together contribute to a healthier energy balance. One-on-one 
counseling that emphasizes foods rich in micronutrients, and that individualizes the 
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counseling to a given patient’s weight status and activity level may prove to be of more 
benefit than general counseling on “healthy” eating.  
Conclusion 
A 2009 conference29 on the state of PAD research concluded that a general 
dearth of pathogenesis studies, a lack of prospective clinical trial-based evidence, and 
an over-emphasis on late-stage treatment interventions all combine to create a clinical 
model in which PAD is underdiagnosed and undertreated. The data from this review 
further supports the need for an expanded research effort that might use nutritional 
prevention approaches to directly lower the PAD burden.  There is adequate preliminary 
evidence that nutrition and weight-loss-based therapies may be useful components of 
PAD treatment. Such nutritional interventions may lower PAD incidence, ameliorate 
functional impairment, and improve ischemic outcomes in PAD patients. These data 
suggest that it is imperative that research in these areas expands further. 
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Box 1 | Risk factors for peripheral arterial 
disease 
 
Lifestyle factors 
■ Reduced physical activity 
■ Tobacco use 
■ Alcohol use 
 
Body composition 
■ Abdominal obesity 
■ High BMI 
■ High ratio of fat:lean body mass 
Nutrition 
■ Insufficient micronutrient intake 
■ Excessive calorific intake 
 
Comorbidities 
■ Hypertension 
■ Insulin resistance 
■ Dyslipidemia 
■ Systemic inflammation 
■ Heart disease 
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Manuscript 2: 
Body composition, nutrient intake and MTHFR genotype in patients with 
peripheral arterial disease. 
 
Abstract 
Objectives: Nutrition guidelines for prevention and treatment of cerebrovacsular and 
cardiovascular diseases are well-established, yet there are no nutritional guidelines for 
patients with peripheral arterial disease (PAD). The purpose of this pilot study was to 
investigate associations between nutritional factors and disease severity in PAD 
patients. A secondary aim was to assess if current data from existing vascular diet 
guidelines are adequate to apply to individuals with PAD. 
Methods: We conducted a cross-sectional study of current nutritional status amongst 60 
free-living PAD patients who were recruited from vascular specialty clinics. Measured 
nutritional variables included dietary intakes, biomarkers of nutritional status, MTHFR 
genotype, serum adiponectin level and body composition, while PAD severity was 
measured by assessment of the ankle-brachial indices, walking ability, PAD-associated 
pain, and psychosocial quality of life.  
Results: Increased dietary fat and cholesterol, low serum vitamin D and adiponectin, and 
increased BMI, total body fat and abdominal adiposity were all associated with more 
severe clinical and psychosocial PAD symptoms. Increased fiber intake was associated 
with greater stair-climbing ability. 
Conclusions: There is preliminary evidence to support the use of CVD lifestyle guidelines 
in PAD treatment, but prospective studies with larger sample sizes are needed. 
Introduction 
Background 
Peripheral arterial disease (PAD) is a pressing public health concern. Despite its 
known high morbidity and mortality amongst cardiovascular diseases (CVD) 23,29, and 
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despite its very high health economic costs 23,156, PAD garners substantially less 
attention. The relationship between established atherosclerosis risk factors for PAD and 
the other two common manifestations of CVD [coronary heart disease (CHD) and 
ischemic cerebrovascular disease] and their known clinical outcomes is complex (Figure 
1). All three of these common atherosclerotic diseases share risk factors, though PAD 
and the other CVDs are biologically not identical. For example, while diabetes mellitus 
(DM) and a history of smoking are both established risk factors for incident CHD and 
stroke, they are particularly strong predictors of PAD risk 9,157. PAD is also distinctive in 
its impact on ambulation and physical function, and is associated with major exertional 
lower extremity ischemic symptoms (claudication) that are experienced as muscle 
fatigue, discomfort, pain and diminished walking capacity. PAD is also the single most 
frequent cause of limb amputation 1, and is often associated with progressive functional 
impairment and profoundly impacts both physical and psychosocial quality of life 1. 
Clinical guidelines have established that pharmacological treatment and 
revascularization procedures can be effective in alleviating PAD symptoms 1,12, however 
the benefits are not always durable 154. Patients often experience post-procedural clinical 
limitations, and even successful revascularization is often associated with a need for 
repeated additional invasive interventions. Thus, this approach is unlikely to be 
sustainable across such a highly prevalent disease 155. Furthermore, patients with 
advanced comorbidities or unstable vascular anatomy may not be viable candidates for 
revascularization, leaving this subpopulation with even fewer treatment options. There 
has been a relative lack of focus in PAD clinical research on methods that might be 
applied to prevent PAD or to minimize its anatomic and clinical progression, as 
compared to efforts to simply provide episodic revascularization. For example, the 2009 
TransAtlantic Vascular Medicine “PAD2009” conference 29 concluded that current 
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guidelines over-prioritize end-stage treatment while overlooking the sizeable population 
of people at risk for developing PAD 1,12.  
The efficacy of nutrition-based programs for CVD prevention and early 
intervention is well-established 158, but there has been insufficient research to develop 
equivalent guidelines to prevent or lower PAD risk via nutritional intervention. Since PAD 
biologically differs from other common CVD, it is possible that the nutritional 
contributions to each PAD risk factor may differ as well. To date, the majority of PAD 
research on nutrition has focused on general dietary trends. These studies by necessity 
have been limited to patients who retain at least moderate walking ability and do not 
suffer from other incapacitating health conditions. As a result the overall nutritional habits 
of PAD patients with diminished physical capacity remain largely unexamined. Given the 
lack of data, there is a critical need to establish whether existing nutrition and body 
composition recommendations for other CVD can be applied to PAD, or whether PAD is 
sufficiently biologically distinct so as to warrant its own clinical recommendations. This 
pilot study aimed to evaluate the nutritional status and body composition of individuals 
with symptomatic PAD. In the long-term, this study establishes the groundwork for a 
larger intervention study that would focus more precisely on specific nutiritonal targets, 
and aim at modifying patients’ PAD symptoms and cinical progression.  
Methods 
Study design 
We conducted a cross-sectional pilot study of the nutritional status and body 
composition of 60 PAD patients.  
Recruitment and study population 
Participants were identified through a search of a university-affiliated hospital 
database and through direct referral from three Twin Cities metropolitan vascular 
specialty clinics. Inclusion criteria included: an established clinical PAD diagnosis, 
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English proficiency, consistent access to a telephone, and the ability to attend research 
clinic visits. Patients were excluded from participation if they were bilateral amuptees, 
had undergone a revascularization procedure within the previous 6 months or if informed 
consent could not be provided due to dementia or other conditions that might impair 
cognition. Patients were initially contacted by telephone and then met at an initial 
screening visit to provide written informed consent. All study documents were approved 
by the University of Minnesota Institutional Review Board. 
Measures 
We assessed the severity of each individual’s PAD burden as a function of 
clinical signs, symptoms and quality of life.  A conceptual model of factors that determine 
PAD severity is presented in Figure 2. Participants were asked to come to a university-
affiliated research clinic for a single three-hour visit that included completion of a survey 
of demographics, lifestyle and medical history. A trained investigator measured height, 
weight and waist and hip circumferences. Each participant underwent a total-body dual 
X-ray absorptiometry (DXA) scan 159 to assess adiposity. Participants were asked to 
complete three non-consecutive 24-hour dietary recall interviews within a two-month 
period, the first conducted in-person, and two additional recalls over the telephone. For 
participants who completed all three recalls, one recall assessed food intake on a 
weekend day, and two recorded weekday intakes. This multi-pass approach to 
assessing nutritional status on varying days of the week is considered to be the optimal 
method for collecting reliable and accurate dietary data 160. A certified interviewer 
assessed eating habits using the Nutrition Data System for Research (NDSR), a 
software application developed at the University of Minnesota Nutrition Coordinating 
Center (NCC) that facilitates standardized recall collection 161. Participants used scale 
models of foods and serving sizes to report their food intake, and were given the NCC 
Food Amounts Booklets for use during telephone surveys. Dietary intakes were 
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calculated using the NCC Food and Nutrient Database 162 and evaluated for portion size, 
ingredients, nutrient composition and preparation methods. Averages were computed for 
analysis. 
Measures of PAD severity included a research visit-based measurement of the 
ankle-brachial index (ABI), completion of the Walking Impairment Questionnaire (WIQ) 
163, and the King’s College Hospital’s Vascular Quality of Life Questionnaire (VascuQOL) 
164. The ABI was measured using a 5-mHz Doppler device (Elite-100R, Nicolet Vascular 
Inc., Golden, CO). Systolic blood pressures were recorded at the brachial arteries of 
both upper extremities, and at the dorsalis pedis and posterior tibial arteries using a 
standard technique 165. The same technique was employed on each patient, regardless 
of the revascularization status of either leg. Each participant underwent two ABI 
measurements while in a supine position and the average of each pair of readings was 
recorded. For analysis of PAD severity for this study, we utilized the lower ABI value for 
each participant. Scores were recorded as continuous measures, as well as categorized 
by standard clinical guideline-based diagnostic cut points 166: abnormal (≤ 0.90), 
borderline (0.91 – 0.99), normal (1.00 – 1.40) or noncompressible (> 1.40). 
The WIQ is a validated 167 20-item survey designed to measure the severity of 
PAD limits physical function. It is the predominant instrument used for capturing self-
reported walking ability in PAD patients with symptomatic claudication and evaluates 
four components: Distance, Speed, Stair Climbing and Pain 1,168. Participants answered 
items on a Likert scale from 0 for “unable to do” to 4 for “no difficulty”, and responses 
were weighted based on the difficulty of each task. When respondents avoided certain 
activities altogether due to PAD symptoms, they were asked to choose “Didn’t do for 
other reasons”.  
The VascuQOL is a validated 25-item survey 164 that assesses patients’ 
perceived quality of life in five domains – Pain, Activity, Symptoms, Emotional and 
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Social. All questions are equally weighted and scored from 1 to 7; for example, in 
response to “In the last two weeks I have had pain in the foot or leg when I am at rest”, 
choosing “All of the time” is coded as a 1, and choosing “None of the time” is coded as a 
7. Domain subscores were calculated as averages of the questions assigned to each 
domain. 
Biomarkers 
A fasting blood sample was collected from each participant, aliquoted and 
separated, and frozen at -20°C until analysis. Folic acid concentrations were assessed 
from whole erythrocytes (chemiluminescent immunoassay, Quest Diagnostics, Wood 
Dale, IL), as this measure is a more valid indicator of long-term dietary folate intake than 
serum folic acid 169. Serum 25(OH)D (ng/mL) was measured using the Diasorin 
LIAISON® chemiluminescence method (Heartland Assays, Ames, IA). Commercially 
available Quantikine human ELISA kits (R&D Systems, Minneapolis, MN) were used to 
measure serum adiponectin concentrations (Kurzer lab, Saint Paul, MN). For 
genotyping, whole blood was extracted using a Qiamp Mini Blood Kit (Qiagen) and 
manufacturer’s protocol. The methylenetetrahydrofolate reductase (MTHFR) gene 
encodes and determines the efficiency of MTHFR, an enzyme that is crucial for folate 
metabolism and homocysteine (Hcy) homeostasis. Amplified 15 ng DNA was assessed 
for MTHFR C667T SNPs using a TaqMan SNP Genotyping Assay (Life Technologies 
Co, Grand Island, NY). The Lightcycler 480 Probes Master (Roche) master mix was run 
under cycling conditions established by the manufacturer and collected on a real time 
PCR machine (Institute of Human Genetics, University of Minnesota Masonic Cancer 
Center, Minneapolis, MN). 
Data analysis 
Outcome variables were selected for biological plausibility and classified into two 
categories: PAD severity as a function of clinical signs or symptoms and PAD severity as 
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a function of psychosocial factors. As this was an exploratory study, in which multiple 
post-hoc analyses were evaluated in a limited patient sample, we purposefully did not 
set any Bonferroni corrections to limit the significance of these multiple comparisons. 
Continuous exposure variables were analyzed against outcomes using linear regression 
modeling; once using the full data set, and again after removing outliers and heavily 
influential data points. Only associations that were significant in both models were 
considered statistically significant. Spearman’s correlation coefficients were generated to 
evaluate monotonic relationships. Ordinal variables were analyzed using Cochran-
Mantel-Haenszel tests and proportional-odds cumulative logit modeling. Statistical 
analyses were conducted using SAS software, version 9.3 (SAS Institute Inc., Cary, 
NC). All p-values are two sided, α = 0.05.  
Results 
Sixty-four PAD patients consented to participation; four withdrew and 60 
underwent data collection. The demographic and body composition characteristics of the 
study cohort are presented in Table 1. There were no significant differences in any 
characteristics by revascularization status, and all revascularized patients had 
undergone their procedures a minimum of 6 months prior to data collection, thereby 
mitigating possibly confounding effects of the revascularization intervention on their 
nutritional habits and status. Half (n=30) of the cohort reported having a previous clinical 
diagnosis of CHD, 9 participants reported a history of stroke, and 4 had a history of both 
conditions. Over a third were diagnosed with DM type 2, and approximately 75% were 
classified as overweight or obese. The characteristics of this cohort are similar to those 
of PAD cohorts in other studies, and to estimates of the general U.S. population 
(approximately 69% overweight or obese) 1,170,171. Further analyses stratifying patients by 
CVD status, diabetes and other associated comorbidities revealed no significant 
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differences in any measures of nutritional status, MTHFR genotype, physical PAD 
severity, or quality of life.  
Nutritional characteristics of these PAD patients are presented in Table 2. 
Twenty-five participants completed all three dietary recalls, two completed two recalls 
and 33 completed only the initial in-person recall. Revascularized patients were 
significantly more likely than patients with native vasculature (NV) to consume a daily 
diet of 2,000 calories or less (p = 0.03). NV patients, however were significantly more 
likely than revascularized patients to consume the minimum recommended daily calcium 
intake (1,000 mg) 172, (p = 0.04).  Participants did not differ by revascularization status 
for any other dietary variable, WIQ component or VascuQOL domain. Over 58% of the 
participants had insufficient or clinically deficient serum 25(OH)D concentrations. For 
MTHFR, five participants were homozygous for the CC wild type, and the remaining 55 
were split between CT and TT genotypes. 
Figure 3 presents results of regression tests for red blood cell (RBC) folate and 
body-mass index (BMI) in relation to various parameters of clinical PAD severity. One-
unit increases in both RBC folate and BMI were significantly associated with lower (more 
severe) WIQ scores; BMI was also inversely associated with WIQ-Stairs scores (data 
not shown, -1.73 ±0.62, p = 0.08; r = -0.32, p = 0.01).  
Figure 4 presents Cochran-Mantel-Haenszel tests between BMI and VascuQOL 
parameters of clinical and psychosocial severity. Waist circumference was significantly 
associated with VascuQOL-Symptoms (p = 0.02) and inversely associated with WIQ-
Stairs (-0.62 ±0.29, p = 0.04; r = -0.27, p = 0.04). Similarly, serum adiponectin was 
inversely associated with WIQ-Distance scores (-19.05 ±5.87, p = 0.002). Two dietary 
variables were associated with WIQ components: cholesterol was inversely correlated 
with WIQ-Pain scores (r = -0.26, p = 0.05), and fiber was positively related to WIQ-Stairs 
(+26.53 ±8.71, p = 0.004; r = +0.26, p = 0.04). The percent of caloric intake as fat was 
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inversely associated with ABI (p = 0.04; r = -0.31, p = 0.02), serum 25(OH)D was 
significantly associated with VascuQOL-Pain scores (p = 0.01), and total energy intake 
was positively associated with WIQ-Distance scores (+3.45 ±1.42, p = 0.02).   
Figure 5 presents significant associations between physical activity and 
psychosocial parameters, namely Total VascuQOL and VascuQOL-Social scores (p = 
0.02, p = 0.005, respectively). Lastly, proportional-odds cumulative logit modeling 
yielded one significant association for dietary fat and ABI: At the 21-35% level of caloric 
intake as fat, the estimated odds of an ABI score below any diagnostic threshold 
(abnormal, borderline, normal, noncompressible) are 0.23 times the estimate of odds at 
the >35% level of fat intake (p = 0.04, CI 0.06 – 0.91). 
Discussion 
Few prior studies have reported the dietary patterns and nutritional status of 
patients with PAD. In our study, participants reported consuming diets high in protein 
and processed meat products, refined carbohydrates (e.g. white bread and pasta), 
saturated fat, cholesterol and added sodium. Participants consumed ≤ 2 servings/day of 
fruits, vegetables and whole grains (versus recommended intakes 173), and despite 
multivitamin supplement use in over half of participants, the majority of participants did 
not meet Daily Recommended Intakes (DRI) 173 for zinc, or vitamins A, C, E or K. These 
observations mirror dietary trends observed in both CVD-specific populations and the 
total U.S. population 174-176.  
This study observed significant associations between markers of increased 
adiposity and greater clinical PAD severity. Higher BMI and waist circumference was 
significantly associated with more severe clinical PAD symptoms. Of 60 participants, 20 
were clinically overweight (BMI 25 to 29.99) and 24 were clinically obese (BMI ≥ 30). 
Both total and abdominal obesity’s association with a range of related conditions, 
including DM and other common CVD are well-established 177,178. Previous research has 
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also established that adiponectin, which is secreted by abdominal lipocytes, is inversely 
correlated with abdominal adiposity and vascular risk 140. We observed that a 1 ng/mL 
increase in adiponectin concentration was associated with a 19-point decrease in WIQ-
Distance scores. To date there have been no other studies of adiponectin and quality of 
life, however our results are supported by Golledge et al’s 57 finding of a positive 
association between serum adiponectin concentrations and mean walking distance in 
PAD patients. Lastly, the association between increased total body fat and greater WIQ-
measured clinical severity, particularly the Stair Climbing component, suggests that of all 
of the above factors; total and abdominal obesity, serum adiponectin and total body fat; 
singly or in combination may be significant predictors of a worsened clinical disease 
burden compared to leaner participants. In support of this, all but three participants had 
waist-to-hip ratios categorized as high-risk 179, and DXA scans of android-gynoid 
adiposity showed that over two-thirds of the participants had ratios over 1.0.  
Nutritional endpoints showed variable associations. The percent of energy intake 
as fat was negatively correlated with ABI score and participants consuming fat calories 
in excess of the recommended 35% 173 experienced significantly greater odds of having 
lower, more severe scores. Greater total energy intake was unexpectedly associated 
with higher WIQ-Distance scores. However, since over half the participants consumed 
fewer than 2,000 calories per day, it is possible that participants with greater energy 
intake were more likely to consume foods rich in nutrients associated with decreased 
clinical severity.  
Dietary cholesterol was correlated with more severe pain symptoms, while 
increased dietary fiber consumption was associated with improved ability to climb stairs. 
As with other CVD, it is thought that dietary fiber influences PAD symptoms by improving 
blood glucose control and by mediating cholesterol synthesis 180. This may explain the 
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especially large increase of an estimated 26 points in WIQ-Stairs scores for every 1 
gram increase in fiber intake. 
 Serum vitamin 25(OH)D was significantly correlated with VascuQOL-Pain scores, 
and participants with increased serum concentrations were more likely to report less 
severe limbic pain. Thirty-five participants had serum 25(OH)D concentrations at 
suboptimal levels (< 30 ng/mL). Hypovitaminosis D is a significant risk factor for both 
PAD 47,67,82 and CHD and stroke 181,182, although the mechanisms for vitamin D’s action 
in vascular etiology remain unclear. Hypothesized pathways include calcification of 
endothelial tissue and increased calcium loss leading to bone pain 102,114,115. Calcium 
metabolism is dependent on vitamin D intake and synthesis, and while the majority of 
participants met daily calcium intake requirements (revascularized participants were 
significantly more likely both to meet intake requirements, and to use calcium 
supplements), our findings suggest inadequate vitamin D might contribute to unabsorbed 
dietary calcium and more severe PAD-related pain. 
 Greater RBC folate concentrations were significantly associated with lower WIQ–
Speed scores, but since the score decrease was very minimal (~one-tenth of a point per 
1 ng/mL), this association is likely spurious. Over 30% of participants were clinically 
deficient in folate, likely resulting from the participants’ generally low intake of folate-rich 
foods (i.e. fruits and vegetables, whole grains). Inadequate folate intake is associated 
with increased CVD and PAD risk, as well as with increased serum Hcy concentrations, 
which is itself an independent risk factor for PAD 1,91. MTHFR genotype might mediate 
these associations, and in this study heterozygous type frequency was nearly identical to 
the general population (45% compared to 43%) 129,130. Unexpectedly, and after re-
confirming genotyping data, we observed that only 8.3% of the participants had the CC 
wild type, compared to 47% in the general population 129,130, and 46.7% was 
homozygous for the TT variant, compared to 5 to 10% of the general population 
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129,130,183. The TT variant encodes a less efficient MTHFR protein (~50% reduced activity 
100), which in turn results in decreased folate metabolism, and may drive increases in 
Hcy concentrations. It remains unclear, however if the TT genotype is an important 
mediator of folate and Hcy-related PAD risk 132,133, and we are unable to substantiate 
why the majority of our participants were homozygous for the variant. Previous CHD and 
PAD genotyping studies have yielded discordant results, with some reporting moderately 
higher frequency of the TT type, and others observing equal or lower frequencies 
100,129,177,183.  
 Lastly, we observed an overall tendency towards decreased VascuQOL-Social 
and Emotional PAD severity in participants with lower BMI and/or more frequent physical 
activity. Although further proportional-odds analysis did not reveal significant 
associations, these trends indicate that more overweight and sedentary patients may 
experience more social isolation and depressed moods than their leaner, more active 
counterparts. Future lifestyle studies of PAD patients should develop more 
comprehensive assessments of psychosocial factors to complement the VascuQOL 
survey. There is evidence that depressive mood disorders are highly prevalent among 
patients with various CVD conditions, and that a depressed state contributes to worse 
vascular outcomes 184-186. Depressed patients may also be less likely to participate in 
research studies, which underscores the need to assure inclusive recruitment 
methodologies.  
To the best of our knowledge, this is the first attempt to comprehensively assess 
markers of PAD severity in relation to patients’  nutrition and body composition. This is 
also the first study to use precise quantitative and qualitative tools to measure PAD 
patients’ dietary habits, without relying on generalized surveys. As participants tended to 
have consistent daily eating habits with minimal intra-personal variation, this strengthens 
the reliability of our findings.  
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There were a number of limitations inherent in this study. First, we note the 
relatively small sample size of this study  Despite this, such a sample size is not unusual 
when PAD treatments or outcomes are measured in other cohorts. As well, the WIQ and 
VascuQOL surveys are validated for PAD patients in studies of this size, are correlated 
187, and we were able detect significant associations. When a limited PAD sample is 
recruited from a vascular specialty clinic (convenience) population, likely reflecting a 
larger PAD disease burden than might be derived from a primary care population, we 
note that our results should thus not be generalized. Patients with severely limited 
physical mobility or age-related cognitive difficulties might differ in eating habits or body 
composition from a broader population-based sample. This study also excluded 
participation of individuals with PAD that were asymptomatic, and excluded individuals 
“at risk” for incident PAD.  As a cross-sectional pilot study, the associations we have 
reported between nutrional variables and PAD severity cannot establish causality. 
Finally, self-reported dietary and lifestyle habits may have been affected by recall bias.  
Conclusions 
These data demonstrate, for the first time, potential associations between clinical 
and psychosocial PAD symptoms and self-reported nutritional status and body 
composition. We observed that individuals with PAD report eating habits that are similar 
to the broader US population and to other cohorts with other CVDs.  These data can 
provide the basis for a much broader cross sectional evaluation of the effect of nutrition 
on incident PAD, on PAD progression, and on recovery from revascularization 
interventions. The current data suggest that individuals with PAD might benefit from 
increased consumption of dietary fiber, vitamin D-rich foods, folate-rich fruits, vegetables 
and whole grains, as well as efforts to promote weight loss for overweight and obese 
PAD patients. These actionable nutritional measures could be incorporated into future 
intervention trials to assess their benefit or harm. Future research can be designed that 
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would confirm the likely impact of nutrition on PAD outcomes and that could inform PAD 
care guidelines, with a potential benefit on both patient outcomes and healthcare costs. 
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Figure 1. Risk factors and outcomes of peripheral arterial disease (PAD), coronary heart disease (CHD) and ischemic stroke. 
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Figure 2. Conceptual model of PAD severity. 
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Table 1. Demographics and body composition characteristics of the study cohort by 
revascularization status
1
. 
 
      Total 
     n=60 (%) 
Native PAD Cohort       
          n=25 (%) 
Revascularization   
      Cohort, n=35 (%) 
       
 Sex      
     Male 40 (66.7) 18 (45.0) 22 (55.0) 
     Female 20 (33.3) 7 (35.0) 13 (65.0) 
       
 Age (mean years ± SD) 68.7 ±10.7 67.8  ±10.4 69.3 ±11.1 
       
 Race/Ethnicity       
White, non-Hispanic 53 (88.3) 22 (41.5) 31 (58.5) 
African-American / African 6 (10.0) 2 (33.3) 4 (66.7) 
Native American 1 (1.7) 1 (100) 0 (0.0) 
       
 Annual Household Income       
     < $20,000 10 (17.0) 4 (40.0) 6 (60.0) 
     $20,000 - $39,999 14 (23.7) 5 (35.7) 9 (64.3) 
     $40,000 - $59,999 12 (20.3) 5 (41.7) 7 (58.3) 
     > $60,000 23 (39.0) 11 (47.8) 12 (52.2) 
       
 Education        
     Some high school 3 (5.0) 0 (0.0) 3 (100.0) 
     High school graduate 6 (10.0) 1 (16.7) 5 (83.3) 
     Some college 13 (21.7) 8 (61.5) 5 (38.5) 
     Technical/vocational training 11 (18.3) 5 (45.5) 6 (54.5) 
     College graduate 17 (28.3) 7 (41.2) 10 (58.8) 
     Postgraduate degree 10 (16.7) 4 (40.0) 6 (60.0) 
       
 Alcohol (drinks8 per week)       
     0 35 (58.3) 16 (45.7) 19 (54.3) 
     1 – 3 12 (20.0) 2 (16.7) 10 (83.3) 
     4 – 6 4 (6.7) 2 (50.0) 2 (50.0) 
     7 + 9 (15.0) 5 (55.6) 4 (44.4) 
       
 Ankle-brachial index2 (index leg)       
Total (mean ± SD) 0.69 ±0.32 0.72 ±0.29 0.67 ±0.35 
> 1.40 (noncompressible) 1 (1.7) 0 (0.0) 1 (100.0) 
1.00 - 1.40 (normal) 5 (8.5) 3 (60.0) 2 (40.0) 
0.91 - 0.99 (borderline) 12 (20.3) 4 (33.3) 8 (66.7) 
≤ 0.90 (abnormal) 41 (69.5) 18 (43.9) 23 (56.1) 
       
 BMI3       
Total (mean ± SD) 28.8 ±5.6 28.7 ±5.2 28.9 ±6.0 
Underweight (< 18.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Normal (18.5 - 24.99) 16 (26.7) 6 (37.5) 10 (62.5) 
Overweight (25.0 – 29.99) 20 (33.3) 8 (40.0) 12 (60.0) 
Obese class I (30.0 – 34.99) 19 (31.7) 10 (52.6) 9 (47.4) 
Obese class II (35.0 – 39.99) 2 (3.3) 0 (0.0) 2 (100.0) 
Obese class III (≤ 40.0) 3 (5.0) 1 (33.3) 2 (66.7) 
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 Medical history       
History of CVD 30 (50.0) 11 (36.7) 19 (63.3) 
History of stroke 10 (16.7) 5 (50.0) 5 (50.0) 
Emphysema and/or COPD 12 (20.0) 5 (41.7) 7 (58.3) 
Cancer  14 (23.3) 4 (28.6) 10 (71.4) 
       
 Atherosclerosis Risk Factors4 
 Current smoker 12 (20.0) 6 (50.0) 6 (50.0) 
     Former smoker 38 (63.3) 17 (44.7) 21 (55.3) 
     Never smoker 10 (16.7) 2 (20.0) 8 (80.0) 
     Type 2 diabetic 21 (35.0) 8 (38.1) 13 (61.9) 
     Hypertensive 45 (75.0) 22 (48.9) 23 (51.1) 
     Obesity diagnosis 10 (16.7) 4 (40.0) 6 (60.0) 
       
 Physical Activity5 (times per week)       
None 4 (6.7) 2 (50.0) 2 (50.0) 
1x 10 (16.7) 6 (60.0) 4 (40.0) 
2 – 3x 12 (20.0) 4 (33.3) 8 (66.7) 
> 3 34 (56.7) 13 (38.2) 21 (61.8) 
       
 Waist circumference6 (cm)       
Total (mean ± SD) 106 ±13.9 107 ±13.8 105 ±14.1 
Low risk (women ≤ 88, men ≤ 102)  36 (60.0) 17 (47.2) 19 (52.8) 
High risk (women > 88, men > 102) 24 (40.0) 8 (33.3) 16 (66.7) 
       
 Waist-to-hip ratio7       
Total (mean ± SD) 0.99 ±0.09 1.01 ±0.09 0.98 ±0.08 
Low risk (Fem ≤ 0.85, Male ≤ 0.90)  3 (5.0) 1 (33.3) 2 (66.7) 
High risk (Fem > 0.85, Male > 0.90) 57 (95.0) 24 (42.1) 33 (57.9) 
       
 Android-gynoid ratio (mean ± SD) 1.07 ±0.19 1.11 ±0.22 1.05 ±0.16 
       
 % Total body fat (± SD) 34.7 ±7.3 34.5 ±5.8 34.8 ±8.2 
       
 % Trunk fat (± SD) 35.3 ±7.2 35.4 ±5.9 35.2 ±8.0 
       
 Serum adiponectin (ng/mL) (mean ± SD) 103 ±76.4 102 ±85.4 103 ±70.6 
       
 
1 p-values not shown – participants did not differ significantly by revasculature status for any characteristic;  
participants with a history of 1+ endovascular or operative procedure(s) to treat PAD were categorized as 
revascularized 
2 Ankle-brachial index values include measures taken from revascularized patients as well as patients with 
native   
   arteries; PAD status was objectively assessed in other ways besides ABI 
3 BMI category definitions from clinical guidelines of the National Institutes of Health (NIH) 
188
 
4 Smoking, diabetes mellitus, hypertension and obesity are established risk factors for PAD 
1
 
5 Physical activity defined as an aggregate of frequency of 15+ minute intervals of mild (minimal effort) 
exercise, moderate (not exhausting) exercise and strenuous (rapid heartbeat) exercise 
6 Waist circumference cut off thresholds from clinical guidelines of the National Institutes of Health (NIH) 
188
 
7 Waist-to-hip ratio cut off thresholds from 2008 World Health Organization Expert Consultation 
179
 
8 An alcoholic beverage contains 0.6 ounces pure alcohol: 12 oz beer, 8 oz malt liquor, 5 oz wine, 1.5 oz 
spirits 
189
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Table 2. Nutritional characteristics
1
 of study cohort by revascularization status
2
. 
 
Total 
n=60 (%) 
Native Vasculature  
n=25 (%) 
Revasculaturizated 
PAD n=35 (%) 
p value3 
        
 Total kcal3         
Total (mean ± SD) 1976 ±788.6 1899 ±720.0 2031 ±840.1 NS 
< 1,500 16 (26.7) 10 (16.7) 6 (37.5)  
1,500 – 1,999 19 (31.7) 3 (15.8) 16 (84.2)  
2,000 – 2,499 15 (25.0) 7 (46.7) 8 (53.3)  
≥ 2,500 10 (16.7) 5 (50.0) 5 (50.0) 0.030 
 Total fat (% of total kcal4)        
Total (mean grams ± SD) 76.8 ±44.5 69.9 ±34.2 81.8 ±50.4 NS 
≤ 20%  3 (5.0) 2 (66.7) 1 (33.3)  
21 – 35% 34 (56.7) 14 (41.2) 20 (58.8)  
> 35%  23 (38.3) 9 (39.1) 14 (60.9) NS 
    
 Dietary n-3 fatty acids (g) (mean ± SD) 10.7 ±1.2 1.5 ±0.8 1.8 ±1.4 NS 
        
 Dietary cholesterol        
Total (mean mg ± SD) 276.9 ±165.2 270.6 ±141.9 281.4 ±181.9 NS 
DRI guideline5 ≤ 300 mg 37 (61.7) 15 (40.5) 22 (59.5)  
Exceeds DRI > 300 mg 23 (38.3) 10 (43.5) 13 (56.5) NS 
 Protein        
Total (mean grams ± SD) 79.3 ±31.7 77.4 ±24.3 80.6 ±36.3 NS 
DRI guideline (≤ 46 g Fem, 56 g Male) 9 (15.0) 4 (44.4) 5 (55.6)  
Exceeds DRI (> 46 g Fem, 56 g Male) 51 (85.0) 21 (41.2) 30 (58.8) NS 
 Carbohydrates        
Total (mean grams ± SD) 238.3 ±112.5 233.6 ±108.6 241.6 ±201.5 NS 
DRI guideline (≤ 130 g) 8 (13.3) 4 (50.0) 4 (50.0)  
Exceeds DRI (> 130 g) 52 (86.7) 21 (40.4) 31 (59.6) NS 
 Dietary fiber        
Total (mean grams ± SD) 22.0 ±16.6 22.3 ±17.5 21.7 ±16.2 NS 
DRI guideline (≥ 25 g Fem, 38 g Male) 5 (8.3) 1 (20.0) 4 (80.0)  
Below DRI (< 25 g Fem, 38 g Male) 55 (90.0) 24 (43.6) 31 (56.4) NS 
 Added dietary sugars        
     Total (kcal) (± SD) 264.1 ±236.0 286.1 ±268.0 248.3 ±212.9 NS 
     DRI guideline ≤ 25% total kcal 56 (93.3) 23 (41.1) 33 (58.9)  
     Exceeds DRI > 25% total kcal 4 (6.7) 2 (50.0) 2 (50.0) NS 
 Caffeinated beverages6 (no. 8-oz servings)        
 ≤ 1.5 14 (23.3) 6 (42.9) 8 (57.1)  
1.6 – 2.5 15 (25.0) 5 (33.3) 10 (66.7)  
2.6 – 4 11 (18.3) 4 (36.4) 7 (63.6)  
> 4 20 (33.3) 10 (50.0) 10 (50.0) NS 
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 Dietary sodium        
Total (mean mg ± SD) 152.1 ±91.3 141.9 ±92.8 159.4 ±90.9 NS 
DRI guideline < 1500 mg 22 (36.7) 11 (50.0) 11 (50.0)  
Exceeds DRI ≥ 1500 mg 38 (63.3) 14 (36.8) 24 (63.2) NS 
 Dietary Calcium7        
Total (mean mg ± SD) 143.9 ±82.1 168.5 ±106.4 126.4 ±54.4 NS 
DRI guideline (≥ 1000 mg) 44 (73.3) 22 (50.0) 22 (50.0)  
Below DRI (< 1000 mg) 16 (26.7) 3 (18.2) 13 (81.3) 0.040 
 Dietary Niacin        
Total (mean mg ± SD) 194.5 ±101.6 207.3 ±121.3 185.3 ±84.5 NS 
DRI guideline (≥ 16 mg) 50 (83.3) 22 (44.0) 28 (56.0)  
Below DRI (< 16 mg) 10 (16.7) 3 (30.0) 7 (70.0) NS 
 Serum 25(OH)D8         
Total (mean ng/mL ± SD) 30.0 ±15.8 32.1 ±19.0 28.4 ±13.2 NS 
Optimal (≥ 30 ng/mL) 25 (41.7) 13 (52.0) 12 (48.0)  
Insufficient (20-30 ng/mL) 20 (33.3) 5 (25.0) 15 (75.0)  
Deficient (< 20 ng/mL) 15 (25.0) 7 (46.7) 8 (53.3) NS 
 Red Blood Cell Folate9        
Total (mean ng/mL ± SD) 665.1 ±182.1 689.3 ±186.6 648.4 ±179.7 NS 
Sufficient (≥ 280 ng/mL) 37 (62.7) 17 (47.2) 19 (52.8)  
Deficient (< 280 ng/mL) 22 (37.3) 7 (31.8) 15 (68.2) NS 
 MTHFR C667T Genotype [count (%)]        
Total 60 (100.0) 25 (41.7) 35 (58.3)  
CC genotype (wild type) 5 (8.3) 2 (40.0) 3 (60.0)  
CT genotype 27 (45.0) 13 (48.1) 14 (51.9)  
TT genotype (variant) 28 (46.7) 10 (35.7) 18 (64.3) NS 
 
1 Nutritient intakes calculated via Nutrition Data System for Research (NDSR) 
161,162,190
  
2 Participants who have a history of 1+ endovascular or operative procedure(s) to treat PAD were categorized as 
revascularized 
3 Participants total caloric intake differed significantly by revasculature status, p = 0.03 
4 Percent of total kcal as dietary fat cut off guidelines from the Department of Health and Human Services 2010 guidelines 
173
 
5 DRI: Dietary Reference Intakes based on Recommended Dietary Allowances (RDA) and Adequate Intake (AI) 
guidelines 
172,191-196
 
6 Caffeinated beverages include regular and half-caffeine coffees, caffeinated teas (black, green and white), caffeinated 
soft drinks 
7 Participants dietary calcium intake differed significantly by revasculature status, p = 0.04 
8 Serum vitamin 25(OH)D cut offs derived from current clinical guidelines 
182
 
9 Red blood cell (RBC) folate (5-methyltetrahydrofolate) cut offs based on diagnostic lab reference ranges 
197
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Figure 3. Regression estimates for red blood cell folate and total body fat (%) in relation to 
each measurement of clinical PAD severity. 
  
a) Estimate for the effect of 1 ng/mL increase in RBC folate on 
WIQ-Speed scores, -0.11±0.02, p < 0.001. 
b) Estimate for the effect of 1 % increase in total body fat on 
WIQ-Overall scores, -1.45±0.36, p = 0.0002. 
  
c) Estimate for the effect of 1 % increase in total body fat on 
WIQ-Speed scores, -1.58±0.44, p = 0.0008. 
d) Estimate for the effect of 1 % increase in total body fat on 
WIQ-Stair Climbing scores, -2.86±0.38, p < 0.0001. 
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Figure 4. Selected Cochran-Mantel-Haenszel associations between BMI
1
 and parameters of 
clinical and psychosocial PAD severity
2
. 
 
  
a) BMI and Total Vascular Quality of Life scores, p = 0.02. b) BMI and VascuQOL Pain Severity, p = 0.01. 
  
c) BMI and VascuQOL Emotional Impact, p = 0.001. d) BMI and VascuQOL Social Impact, p = 0.01. 
1 Cut off points for BMI based on current World Health Organization definitions of normal weight, overweight, obesity and 
extreme obesity 
198
 
2 VascuQOL-Pain categorized as a parameter of clinical PAD severity; VascuQOL-Total, -Emotional Impact and –Social 
Impact categorized as parameters of psychosocial PAD severity. 
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Figure 5. Selected Cochran-Mantel-Haenszel associations
 
between frequency of physical 
activity
1
 and parameters of psychosocial PAD severity. 
  
a) Cochran-Mantel-Haenszel association between self-
reported Physical Activity, p = 0.02 
b) Cochran-Mantel-Haenszel association between self-  
    reported Physical Activity, p = 0.005. 
1 Physical Activity defined as aggregate of frequency of 15+ minute increments of Mild (e.g. easy walking, bowling, golf), 
Moderate (e.g. fast walking, baseball, tennis, easy bicyling, easy swimming, yoga) or Strenuous (e.g. running, vigorous 
swimming, long distance bicycling, soccer, football) physical activity. 
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Manuscript 3: 
Recruitment challenges: obstacles to enrolling patients with peripheral arterial 
disease (PAD) for a feasibility study of nutrition and body composition. 
Key words: recruitment, vascular disease, peripheral arterial disease, elderly, 
nutrition, diet, obstacles, challenges 
A. Abstract 
Objectives: To describe recruitment to a cross-sectional pilot study of nutritional status 
and body composition in patients with peripheral arterial disease (PAD). PAD is a group 
of syndromes characterized by both chronic and progressive atherosclerosis with a high 
burden of cardiovascular morbidity and mortality. 
Methods: Potential subjects were identified either from hospital billing records or 
referred directly by vascular clinics. Patients were invited to participate, and recruited 
subjects were asked to come to a research clinic for data collection.  
Results: Between May 2012 and April 2013, 1,446 patients were identified. One 
hundred sixty-five patients (11.4%) responded to recruitment requests. Of the 
responders, 34 (20.6%) were deemed ineligible, 20 (12.1%) declined to participate, and 
we were unable to sustain sufficient contact with 47 (28.5%) patients to complete the 
consent process. The final enrollment was 64 participants (64/1,446; 4.4%), and 4 
subjects (6.3%) subsequently withdrew from the study prior to data collection. 
Conclusions: Recruiting PAD patients for a nutrition study presents a variety of 
challenges, due largely to the burdens of living with PAD and coexistent illnesses, and 
patients’ reluctance or inability to travel for research. 
B. Introduction 
Definitions and Prevalence 
 Peripheral Arterial Disease (PAD), also known as Peripheral Vascular Disease 
(PVD) comprises a range of vascular syndromes. Characterized by arteriosclerosis in 
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vasculature other than the heart or brain, the term most commonly refers to 
atherosclerotic disease in the infrarenal aorta and the lower extremities1. PAD is 
essentially a disease of systemic inflammation. Fatty plaque deposits on arterial walls 
diminish or block blood flow, which can lead to thrombosis or thrombotic embolism1. 
Similarly, thinning and dilation of the lumen or dysplastic thickening may also impair 
blood flow, eventually forming aneurysms1. PAD is the most common cause of limb 
amputation, and regardless of localization or type of stenosis, all PAD syndromes are 
associated with a significant risk of cardiovascular events, including infarction and 
stroke1,12. PAD patients are also at a significantly increased risk of cardiovascular 
disease (CVD)-related mortality, with rates exceeding those for CVD alone23,29.  
At any point, up to 14% of Americans have PAD, and it is estimated that there 
are over 10 million sufferers in all of North America16,199,200. Accurate data are difficult to 
collect, however, as half to two-thirds of affected people are asymptomatic prior to an 
ischemic event14, and prevalence estimates do not account for people whose clinical 
measures fall on the cusp of official diagnosis1. Established risk factors for PAD include 
smoking, diabetes mellitus, dyslipidemia, hypertension, obesity and a family history of 
CVD or PAD4,5. As a result, patients experience a high frequency of comorbid conditions 
that can exacerbate atherosclerotic progression1,201. Finally, the health cost burden of 
PAD is also significant. Over 21 billion dollars are spent annually on treatment in the 
U.S., which surpasses CVD treatment expenditures by up to 23%23,29.  
Treatment Approaches 
 Clinical guidelines for PAD treatment center around two concerns: improving 
patients’ quality of life, and decreasing the risk of incident CVD events1,12. Clinicians 
often initiate treatment with pharmacological interventions, and these focus on mitigating 
the pain and impaired walking ability that are hallmarks of PAD, and on modifying risk 
factors that contribute to ischemic risk. The former may be treated with analgesics, while 
50 
 
the latter are treated with medications such as lipid-lowering statins, anti-thrombotics 
and glycemic control drugs for diabetics. Additionally, depending on a patient’s age, 
vascular anatomy and comorbid conditions, clinicians will employ revascularization 
procedures to restore blood flow in affected arteries. Revascularization may take the 
form of less-invasive endovascular procedures, for instance balloon angioplasty or 
thrombolysis, or more invasive open surgery such as bypass grafting or necrotic tissue 
resection1,12,201. 
 Nevertheless, PAD is a progressive illness, and the benefits of revascularization 
are generally not durable, regardless of treatment type154. Additionally, revascularization 
procedures frequently result in complications that require repeated intervention, and 
further contribute to disease and health cost burdens155. A recent clinicians’ conference29 
reported that PAD is generally underdiagnosed and undertreated, and that an emphasis 
on late-stage treatment has created gaps in research relative to other vascular diseases. 
Consequently, there is an emerging body of research in lifestyle-based therapies for 
preventing or treating PAD, particularly exercise25-27, and to a smaller degree nutrition177. 
Obstacles to Research 
 In the nascent area of nutrition research, studies of PAD patients have largely 
relied on subpopulations of epidemiological cohorts177. These studies reported 
generalized observations of eating habits and dietary patterns, and broadly delineated 
some nutrients of interest. More specific investigations of patients’ nutritional status, 
however, have come across significant challenges. Sample sizes are small, ranging from 
1692 to 23242 in cross-sectional, prospective and randomized trial studies alike177. PAD 
patients tend to be older, have multiple comorbidities and have diminished physical 
mobility1,24, all of which create a population that is difficult to recruit and retain.  
Small sample sizes limit the validity of nutrition studies in PAD research. Internal 
biases, such as convenience sampling and self-selection bias by healthier patients 
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hinder the generalizability of study results to a wider population. The inability to recruit 
sufficiently large cohorts also has implications for clinical practice.  Small sample sizes 
limit the ability to detect potentially significant associations and outcomes, calling into 
question whether taking advantage of patients’ time and investigators’ resources is 
useful or ethical. Describing obstacles to recruitment and retention is an important step 
in expanding the body of research on nutrition and PAD, and is crucial to developing 
evidence-based recommendations for clinical practice. In this paper, we describe the 
experiences and obstacles encountered while recruiting patients for a cross-sectional 
study of nutritional status, body composition and PAD severity.    
C. Methods and Analysis 
 Recruitment and data collection took place simultaneously and lasted 12 months, 
from May 2012 to April 2013. Inclusion criteria were: a clinical diagnosis of PAD, at least 
one intact leg, English proficiency, consistent access to a telephone and the ability to 
procure one’s own transportation to and from the research clinic. Initially, all identified 
patients were considered eligible for recruitment regardless of revascularization status, 
however patients were excluded if they had undergone revascularization procedures 
within the previous 6 months. In an effort to delineate more precisely the associations 
between nutrition, body composition and PAD severity, recruitment criteria were 
modified at the 6-month mark to prioritize patients with native vasculature. Exclusion 
criteria included: unconfirmable PAD diagnosis, lack of English literacy, lack of 
transportation, as well as any patients who were double leg amputees, were wheelchair-
bound, or had diminished ability to provide informed consent due to dementia, 
Alzheimer’s disease or other cognitive limitations. 
 Patients who met all inclusion criteria were invited to participate via telephone or 
letter, and completed the consent process in person at the research clinic. Each 
participant was asked to complete one clinic visit, and two telephone dietary interviews. 
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Table 1 presents data collection variables. Participants were asked to fast for a 
minimum of 8 hours prior to their clinic visits, and were offered a full breakfast 
immediately after completing a blood draw. As compensation for their time, participants 
were given modest financial reimbursement after the clinic visit, and again after 
completing both telephone dietary interviews. Consent forms stipulated that if blood tests 
indicated any abnormality (e.g. vitamin D deficiency), patients would be notified and 
given information to convey to their physicians. 
All data were examined for completeness and accuracy. Outcome variables were 
selected for biological plausibility and classified into two categories; PAD severity as a 
function of clinical signs/symptoms and PAD severity as a function of psychosocial 
factors. Continuous exposure variables were analyzed against outcomes using linear 
regression modeling. Spearman’s correlation coefficients were generated to evaluate 
monotonic relationships. Ordinal variables were analyzed using Cochran-Mantel-
Haenszel tests and proportional-odds cumulative logit modeling.  
D. Results 
A university-affiliated health care organization conducted a database search of all 
patients with PAD-related billing entries in the greater Minneapolis/St. Paul area. A total 
of 1,374 people was identified, and each patient was mailed a recruitment packet 
consisting of contact information, a summary of the study, transportation directions and a 
consent form. Additionally, vascular clinicians from three area hospitals screened and 
referred PAD patients to the study. Clinicians personally provided information to patients 
they deemed eligible candidates for participation, and with a patient’s consent, his/her 
contact information was provided to the study coordinator. Seventy-two patients were 
identified using this method, yielding a total of 1,446 potential participants. 
Of the 1,374 PAD patients mailed recruitment packets, 93 (6.8%) contacted the 
study coordinator. Including the 72 patients referred by clinicians, recruitment was 
53 
 
attempted with a total of 165 patients, or 11.4% of the initial pool. Of these, 39 (23.6%) 
declined to participate. All reasons for non-participation are presented in Table 2. Most 
frequent reasons were either an inability to maintain contact with patients to proceed 
with obtaining consent and scheduling, or difficulty with transportation to the research 
site. An additional 28 (17%) patients could not be contacted at all, and 34 (20.6%) 
patients were considered ineligible. A total of 64 patients consented to participation, and 
four participants did not attend their scheduled visits. Follow up telephone calls were 
made to establish reasons for non-attendance; 2 participants had difficulty with driving to 
or finding the clinic, and 2 declined to give a reason. Of the 60 remaining participants, 25 
(41.7%) completed the clinic visit and both telephone interviews. Two patients completed 
only one additional telephone interview, and 33 (55%) solely attended the clinic portion 
of the study. Upon finishing their clinic visits, 3 of the 35 non-completes declined to take 
part in telephone interviews, but gave no reason for doing so. The remaining 32 
participants were considered non-completes as they could not be reached after repeated 
follow up attempts. There were no significant differences (clinical or otherwise) between 
patients who completed the study, partially completed or dropped out. 
E. Discussion 
This study underscores the difficulties inherent in recruiting PAD patients for a 
study of nutrition and body composition. Patients were excluded primarily for having a 
history of revascularization (if recruited after the 6-month midpoint of the study) or for 
being unable to confirm their PAD diagnoses. Among the unconfirmable cases, 2 
categorically denied having a PAD diagnosis, whereas the remaining patients stated that 
they “likely” or “probably” had been diagnosed with PAD, but were struggling at the time 
with other chronic illnesses. These patients could not recall if their clinicians had 
mentioned PAD to them when discussing their various treatments, but when asked to 
elaborate further, reported having PAD-like symptoms (intermittent claudication or critical 
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limb ischemia13). This observation has been reported in other papers, where a high 
prevalence of comorbid conditions coupled with patients’ lack of familiarity with PAD 
result in a more limited pool of eligible subjects24,201. More recently, an evaluation of 
strategies for recruiting Latino PAD patients for an exercise intervention encountered 
similar difficulties202. Throughout our recruitment efforts, potential participants reported a 
variety of comorbidities that influenced their decision whether or not to participate. 
Patients expressed that diminished physical function due to CVD, diabetic neuropathy, 
emphysema, COPD and after-effects of strokes and related surgeries contributed to a 
disease burden that made the daily business of living difficult, including those patients 
that consented to participation. 
The second key reason for non-participation related to transportation. Patients 
who declined to participate for this reason stated that they either: One, physically felt 
unable to drive and did not have a friend or relative to drive them; Two, considered 
themselves able drivers but felt anxious about navigating an urban area; or Three, said 
they were able drivers, but deemed making the trip to participate in a study to be too 
burdensome. While there is a wide-ranging network of public transportation in the 
Minneapolis/Saint Paul metro area, very few potential subjects were willing to consider 
utilizing this option. 
It is difficult to discern to what extent transportation was an obstacle due to 
patients’ disease burden or because of other factors. An important alternate factor may 
be age. PAD and other vascular diseases tend to affect people aged 50 and older, but 
many patients are over the age of 6516. As a result, the declining physical mobility and 
cognitive function that are characteristic of aging may have a substantial impact on 
patients’ receptiveness to recruitment. Several reviews have concluded that older adults 
comprise a uniquely challenging population in study recruitment, and are therefore 
significantly under-represented in clinical research203-207. A whole range of factors 
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shapes this dynamic, but most common among them are the aforementioned issue of 
transportation, as well as the difficulty of identifying and contacting potential subjects 
who are functionally limited and/or homebound. Moreover, a general mistrust of 
interacting with strangers or medical professionals is a recurring observation. Reviewers 
reported that older patients tend to approach people unknown to them with suspicion, 
and frequently feel wary of sharing personal information with researchers203-205,207. Lastly, 
older patients regularly express a misperception regarding the purpose of research 
studies206, and many confusedly view participation as an optional or unnecessary 
component of clinical treatment207. 
It is possible that a combination of these reasons prevented the majority of 
identified PAD patients (93.2%) from considering participation in this study. There is an 
overall consensus that the existing body of literature has provided scant or incomplete 
descriptions of techniques used for recruiting older participants203-208, further limiting the 
ability to identify the methods that may be most efficacious. Nevertheless, there are 
approaches that future researchers may use to improve recruitment. Identifying and 
contacting older subjects in statistically significant numbers requires an especially large 
input of resources, manpower and time204. Enlisting the assistance of physicians that 
directly interact with patients can be an important source of participants206,207. Physicians 
contend with a heavy workload and may not be willing or able to use time with patients 
to relay information about a research study, particularly when they feel they have no 
personal incentive to do so206,209. Consideration should be given to establishing a 
mutually beneficial partnership with health care providers and organizations – one that 
encourages clinicians to incorporate study recruitment into daily interaction with patients, 
while researchers share findings in an immediately translatable and clinically relevant 
manner. Such an approach may be more effective than mail-outs to patients identified 
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via hospital billing records – a method that ultimately did not produce a high yield of 
recruits in this study. 
During the planning stage, recruitment of older subjects should also incorporate 
input from the target population itself. Focus groups and clinic-based interviews of older 
patients can delineate what methods and inducements may be most likely to attract 
potential subjects, and create a greater sense of researcher-subject cooperation in the 
process203,205. Piloting the recruitment strategy with a small representative sample can 
then help refine the study plan further205, and clarify issues with written materials, 
consent forms, etc. that may be burdensome or convoluted for older patients207. Finally, 
consideration should also be given to structuring studies so that recruitment and data 
collection take place in the same location, preferably the same locations where patients 
receive regular care, thereby mitigating difficulties with transportation.  
 The racial/ethnic makeup of the target population may be a less apparent, but 
possibly significant reason for our difficulty recruiting PAD patients. Minorities in general 
and African Americans in particular carry a disproportionately higher burden of both PAD 
and CVD, with greater rates of limb amputation and vascular-related mortality than their 
Caucasian counterparts20,21,147. This study recruited subjects from a racially diverse 
region – over 17% of the metro-area population belong to a minority race or ethnicity, 
primarily Latinos and African Americans210. Nonetheless, out of 60 participants none 
were Latino, and 6 identified as black/African American. While this constitutes 10% of 
the cohort, oversampling African Americans was an important study goal that remained 
unmet. 
 There is a variety of explanations for this outcome. Both public health and clinical 
care institutions are generally unaware of the importance of screening for PAD and its 
highly prevalent risk factors4. For minority groups like African Americans, however, this 
phenomenon is exacerbated further. Evaluations of racial disparities in research have 
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observed that African Americans with PAD make use of medical care less frequently 
than Caucasians, and if diagnosed, tend to receive less comprehensive 
treatment21,211,212. Parsing the causes, socioeconomi and otherwise, of systemic 
racial/ethnic disparities in medical treatment is beyond the scope of this paper. 
Nonetheless, in regard to recruiting minorities for a PAD study, the recurring issue of 
mistrust may be especially pertinent. Various studies have concluded that past abuses 
of research subjects and culturally-imbedded mistrust of physicians disinclines African 
Americans and other minorities from participating in clinical research213-215. Older 
minorities are also markedly wary of interacting with researchers216, and mistrust arising 
from both advanced age and race/ethnicity may have discouraged the PAD patients 
contacted for this study from being receptive to recruitment. 
  Even so, there is evidence to suggest that this population’s distrust of clinicians 
and researchers may be effectively mitigated in future studies. Communication is a 
primary concern; studies have reported that minorities feel physicians are frequently 
vague in their communication to patients and provide insufficient information about their 
illnesses and treatments213,217. When asked to participate in studies, minorities have 
stated that they are inclined to think researchers will intentionally withhold important 
details of study involvement214,216, and even subject participants to unnecessary risks214. 
The process of informed consent may be perceived as confusing and misleading as 
well218. In order to address these concerns, more recent studies have attempted other 
methods with measurable success. Clinical studies of African Americans and Latinos 
reported that community-based participatory research (CBPR)219, in which community 
representatives are involved in study design, recruitment and implementation, have 
yielded significant rates of recruitment and participation220-223. As a non-traditional 
approach, CBPR bypasses institution-based research and brings data collection efforts 
to subjects’ home areas. In doing so, transportation difficulties are also largely avoided. 
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Furthermore, participants have reported feeling personally invested in the success of 
such studies220, and have helped to modify study materials so that they are culturally 
tailored to the target population222. A CBPR-like approach may be effective in PAD 
research, regardless of patients’ racial/ethnic background, and should be considered as 
a viable option in future studies.  
 Finally, mental health may also be a significant mediator of study recruitment. 
There is considerable evidence that mood disorders, particularly depression, are 
significantly associated with CVD. Prevalence studies have observed that having 
depressive symptoms is an independent risk factor for CVD and CVD events185,224-227. 
The Nurses’ Health Study reported that depression was a significant risk factor for CVD-
related mortality in women228, and an assessment of Australian patients found that self-
reported mental health was a greater predictor of CVD outcomes than self-reported 
physical health229.  
 PAD studies have reached comparable conclusions184,230. A large 
epidemiological study of 1,024 CVD patients observed a significant positive association 
between depressive symptoms and both prevalent PAD and ensuing PAD events186. 
Remes et al’s231 case-control assessment of 131 PAD patients similarly reported 
significantly worse scores on depressive symptom surveys compared to matched 
healthy controls. Studies of PAD patients’ physical function also mirror these findings; 
depressive symptoms are associated with greater pain and decreased maximum walking 
ability232, as well as a faster rate of functional decline in depressive versus non-
depressed patients233. Lastly, investigators reported that depressive patients who have 
undergone revascularization treatment consistently report worse post-procedural 
symptoms234, and experience a higher incidence of CVD events and mortality than non-
depressives235. 
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 Beyond the worsened mood states that can accompany physical decline in 
people with PAD, there is much that is still unknown about the role of mental health in 
treating the disease, and to date there have been no studies of mental health in PAD 
recruitment. Whereas the American Heart Association recommends screening for 
depression in all vascular patients, this guideline is consistently disregarded and mood 
disorders largely remain untreated225. Such a dynamic need not continue, however, and 
consideration should be given in future PAD studies to screen potential subjects for 
depression, regardless of whether they have a previously-established clinical diagnosis. 
If as a result it becomes evident that depressive patients largely decline study 
participation, such an observation should form the basis for revising recruitment 
approaches, possibly by collaborating with mental health clinicians and social workers 
who specialize in elderly populations, and who are trained to provide mental health care. 
Recently, a small intervention trial found that after 2 months of home-based, self-
administered mood therapy education, 13 PAD patients experienced a significant 
improvement in depressive symptoms and overall mental health236. Such a finding is 
preliminary and must be replicated with larger cohorts. Nevertheless, it offers the 
possibility that addressing mental health issues in a non-clinical setting may be 
beneficial both to patients and for recruitment efforts. Assessments of the homebound 
elderly additionally concluded that this population (which is more likely to suffer from 
depression than able-bodied counterparts), experiences very limited improvement in 
mood using pharmacological treatment237, which further supports the use of alternative 
methodologies.  
F. Summary and Conclusion 
This paper evaluated the feasibility of recruiting vascular patients for a study of 
nutritional status, body composition and PAD severity. Primary obstacles to recruiting a 
statistically significant number of participants included patients feeling burdened by their 
60 
 
symptoms and coexistent chronic illnesses, and difficulties with using or obtaining 
transportation. As a cross-sectional viability investigation, this study had relatively limited 
resources and was unable to employ multi-site recruitment. Nevertheless, data collection 
was completed and results of patients assessments are presented elsewhere. 
Challenges in recruiting and retaining subjects should be addressed in future studies, 
and there is a body of evidence that offers potentially useful strategies. Consideration 
should be given to community- and home-based recruitment, particularly in cooperation 
with community representatives. Special emphasis should be placed on collecting 
stakeholders’ feedback on how best to approach potential participants and how to tailor 
study materials to maximize clarity and ease of use. Whenever possible, data collection 
must take place either in subjects’ home environments or in the clinical settings where 
they already receive regular care. Such an approach can alleviate difficulties with 
transportation, and help build a more fruitful partnership with clinical organizations . 
Moreover, if recruitment takes place in health care settings that predominantly serve 
racial and ethnic minorities, this will allow for data collection from a more diverse cohort. 
Finally, in order to address the significant issue of depressive mood disorders in 
patients, PAD researchers should give strong consideration to partnering with mental 
health care providers and specialized social workers. While these strategies will still limit 
recruitment to the symptomatic, diagnosed sub-population PAD patients, they will 
contribute to a more efficient and effective  methodology. 
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Table 1. Variables of interest in a cross-sectional study of nutritional status, body 
composition and disease severity in patients with peripheral arterial disease 
(PAD). 
 
Category Variable Measurement 
Biomarkers
a
 Vitamin D Serum 25(OH)D 
 Folic acid Red blood cell folate 
 Adiponectin Serum adiponectin 
 MTHFR activity MTHFR genotype 
   
Body composition Body mass BMI (kg/m
2
) 
 Abdominal adiposity Waist, hip circumferences 
 Total adiposity Whole-body DXA scan 
   
PAD severity
b
 Peripheral blood flow Ankle-Brachial Index (ABI) 
 Walking ability Walking Impairment Questionnaire (WIQ) 
 Pain, related symptoms WIQ + Vascular Quality of Life Survey (VascuQOL) 
 Psychosocial stressors VascuQOL 
   
Diet and nutrition Nutrient intakes 
Nutrition Data System for Research (NDSR)
c
 
 Eating habits 
   
Other Demographics
d
 
Surveys 
 Medical history
e
 
 
a Serum 25(OH)D and red blood cell folate are validated markers of long-term dietary status
169,182
; MTHFR, 
Methylenetetrahydrofolate reductase - an enzyme necessary to folate metabolism 
b ABI is the standard diagnostic tool for PAD
1
; WIQ and VascuQOL questionnaires are validated surveys of symptoms, 
walking ability and quality of life in people with vascular disease
163,164
 
c NDSR is a standardized, validated program for collecting 24-hour dietary recall data
161,162
 
d Demographic variables included questions about age, race/ethnicity, income, education and marital status 
e Medical history variables included smoking history, frequency and type of physical activity and history of diagnoses of 
CVD, obesity, pulmonary conditions, cancer, hypertension and diabetes mellitus 
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Table 2. Reasons for non-participation. 
 
Classification (n = 77) Reason Detail n 
Expressed interest (n = 23) Could not be reached after initial contact 19 
 Consented, but dropped out prior to data collection 4 
   
Not interested (n = 20) Unable or unwilling to procure transportation 11 
 Too busy, work responsibilities 2 
 No reason given 7 
   
Ineligible (n = 34) History of revascularization(s) 14 
 Unconfirmable PAD diagnosis 11 
 Double leg amputee 3 
 Dementia / Alzheimer’s disease 2 
 Wheelchair-bound 1 
 Recent bodily injury 1 
 Lack of English proficiency 1 
 Deceased between initial contact and follow up 1 
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Appendix A. Demographic Survey 
 
Demographics & Medical History 
 
General Questions About You: 
 
1.   
What is your gender?   
 Male  1     
 Female  2 
   
2.   
What is your age?  ___________years   
    
    
3.    
What is the highest level of education you have completed? 
 Some high school  1 
 High school graduate  2 
 Some college  3 
 Technical/vocational training  4 
 College graduate  5 
 Postgraduate degree  6 
    
4.    
What is your total yearly household income? 
 Less than $10,000  1 
 $10,000 to $19,999  2 
 $20,000 to $39,999  3 
 $40,000 to $59,999  4 
 $60,000 to $79,999  5 
 $80,000 to $99,999  6 
 $100,000 or more  7 
    
5.    
What is your current marital status? 
 Single, never married  1 
 Married  2 
 Separated  3 
 Divorced  4 
 Widowed   5 
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6.    
What is your race/ethnicity? 
 Caucasian   1 
 Hispanic / Latino  2 
 African-American  3 
 Native American  4 
 African (Somalia, Ethiopia, etc.)  5 
 Asian   6 
 East Indian   7 
 Middle Eastern  8 
 Other _______________  9 
    
Regarding Your Medical History and Personal Habits: 
 
   
1.   
On average, how many alcoholic beverages do consume in one week? 
(Note: One drink = 1 can or bottle of beer, one shot of liquor, or 4 ounces of wine) 
 0  1 
 1 - 3  2 
 4 – 6  3     
 7 – 10  4 
 More than 10  5 
   
2.   
Which statement best describes your cigarette smoking habits? 
 I have never smoked.  1 
 I used to smoke, but don’t anymore.  2 
 I currently smoke, but only 
occasionally. 
 
3 
 
 I smoke on a daily basis.  4 
    
3.    
Considering an average week, how often do you do strenuous exercise (heart 
beats rapidly) for more than 15 minutes?                                
(examples: running, vigorous swimming, long distance bicyling, soccer, football) 
 Never  1 
 Once per week  2 
 2 to 3 times per week  3 
 More than 3 times per 
week 
 
4 
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4.    
Considering an average week, how often do you do moderate exercise (not 
exhausting) for more than 15 minutes?                                       
(examples: fast walking, baseball, tennis, easy bicycling, easy swimming, yoga) 
 Never  1 
 Once per week  2 
 2 to 3 times per week  3 
 More than 3 times per 
week 
 
4 
 
    
5.    
Considering an average week, how often do you do mild exercise (minimal 
effort) for more than 15 minutes?   (examples: easy walking, bowling, golf) 
 Never  1 
 Once per week  2 
 2 to 3 times per week  3 
 More than 3 times per 
week 
 
4 
 
    
6.    
What medications for PAD have you taken (in the past or currently)? 
 Prescription blood thinners  1 
 Cholesterol-lowering drugs  2 
 Over-the-counter blood thinners 
(aspirin) 
 
3 
 
    
7.    
What surgeries have you had to treat your PAD? 
 None  1 
 Stent (one)  2 
 Stents (more than one)  3 
 Amputation  4 
 Stents & amputation  5 
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8.    
Have you ever been diagnosed with any of the following? (mark all that apply) 
 Heart disease  1 
 Stroke  2 
 High blood pressure  3 
 Diabetes (type 2)  4 
 Insulin resistance / Pre-diabetes  5 
 Emphysema  6 
 COPD (Chronic Obstructive Pulmonary 
Disease) 
 
7 
 Cancer  8 
 Obesity  9 
PLEASE STOP HERE 
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Appendix B. BMI, Waist/Hip Circumferences and ABI Data Sheet 
 
BMI 
 
 
 
 
 
ABI 
Arms 1st 2nd 
 
Average 
 
  
Right       
 
   Highest 
Average Arm: 
 
R       L 
Box A 
Left       
 
   
Ankles 1st 2nd 
 
Average 
 
  
Right DP       
 
   Highest RIGHT 
Average Ankle: 
 
DP       PT 
Box B 
Right PT       
 
   
Left DP       
 
   Highest LEFT 
Average Ankle: 
 
DP       PT 
Box C 
Left PT       
 
   
 
 
Box B__________          ÷          Box A__________          =                                  Right 
ABI 
 
 
Box C__________          ÷          Box A__________          =                                  Left 
ABI 
 
 
Notes:__________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
     HT_________cm           WT_________kg                 BMI_________ 
 
 
 
WC_________cm HC_________cm 
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Appendix C. Walking Impairment Questionnaire 
 
Walking Impairment Questionnaire (WIQ) 
Walking Impairment: These questions ask about the reasons why you are having 
difficulty walking. We would like to know how much difficulty you had walking during 
the past week. By difficulty, we mean how hard it was or how much physical effort it 
took to walk because of each of these problems. 
 Pain Severity 
 No 
Difficulty 
Slight 
Difficulty 
Some 
Difficulty 
Much 
Difficulty 
Unable     
To Do 
Didn’t 
Do For 
Other 
Reasons 
1 
Pain, stiffness or aching 
in your joints (ankles, 
knees or hips)? 

4 

3

2

1

0 
 
2 
Weakness in one or both 
of your legs? 

4 

3

2

1 

0 
 
3 
Pain or discomfort in 
your chest? 

4 

3

2

1 

0 
 
4 Shortness of breath? 
4 

3

2

1 

0 
 
5 Heart palpitations? 

4 

3

2

1 

0 
 
6 
Other problems? (Please 
list). 
 
 

4 

3

2

1 

0 
 
Walking Distance: Report the degree of physical difficulty that best describes how hard 
it was for you to walk on level ground without stopping to rest for each of the following 
distances during the last week. 
 Distance 
 No 
Difficulty 
Slight 
Difficulty 
Some 
Difficulty 
Much 
Difficulty 
Unable     
To Do 
Didn’t 
Do For 
Other 
Reasons 
1 
Walking indoors, such as 
around your home? 

4 

3

2

1

0 
 
2 Walking 50 feet? 

4 

3

2

1 

0 
 
3 
Walking 150 feet (½ 
block)? 

4 

3

2

1 

0 
 
4 
Walking 300 feet (1 
block)? 

4 

3

2

1 

0 
 
5 
Walking 600 feet (2 
blocks)? 

4 

3

2

1 

0 
 
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6 
Walking 900 feet (3 
blocks)? 

4 

3

2

1 

0 
 
7 
Walking 1500 feet (5 
blocks)? 

4 

3

2

1 

0 
 
Walking Speed: Report the degree of difficulty that best describes how hard it was for 
you to walk one city block on level ground at each of these speeds without stopping to 
rest during the last week. 
 Speed 
 No 
Difficulty 
Slight 
Difficulty 
Some 
Difficulty 
Much 
Difficulty 
Unable     
To Do 
Didn’t 
Do For 
Other 
Reasons 
1 Walking one block slowly? 

4 

3

2

1

0 
 
2 
Walking one block at an 
average speed? 

4 

3

2

1 

0 
 
3 
Walking one block 
quickly? 

4 

3

2

1 

0 
 
4 
Running or jogging one 
block? 

4 

3

2

1 

0 
 
Stair Climbing: For each of these questions, report the degree of physical difficulty that 
best describes how hard it was for you to climb stairs without stopping to rest during 
the past week. 
 Stairs 
 No 
Difficulty 
Slight 
Difficulty 
Some 
Difficulty 
Much 
Difficulty 
Unable     
To Do 
Didn’t 
Do For 
Other 
Reasons 
1 
Climbing one flight of 
stairs? 

4 

3

2

1

0 
 
2 
Climbing two flights of 
stairs? 

4 

3

2

1 

0 
 
3 
Climbing three flights of 
stairs? 

4 

3

2

1 

0 
 
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Appendix D. Walking Impairment Questionnaire (WIQ) Scoring 
 
   
Pain Weight Denominator 
Question 1 2 
88 
Question 2 2 
Question 3 3 
Question 4 4 
Question 5 5 
Question 6 6 
   
Distance   
Question 1 20 
14,080 
Question 2 50 
Question 3 150 
Question 4 300 
Question 5 600 
Question 6 900 
Question 7 1,500 
   
Speed   
Question 1 2 
46 
Question 2 2 
Question 3 3 
Question 4 5 
   
Stairs   
Question 1 1 
24 Question 2 2 
Question 3 3 
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Appendix E. Vascular Quality of Life Questionnaire (VascuQOL) 
 
Vascular Quality of Life Questionnaire (VascuQOL) 
 
Instructions: These questions ask you how you have been affected by poor circulation to 
your legs over the last two weeks. You will be asked about the symptoms you have had, 
the way that your activities have been affected and how you have been feeling. Please 
read each bit of the answer and then tick the one that applies best to you. If you are 
unsure about how to answer a question, please give the best answer you can.  
There is no right or wrong answer. 
Please answer every question.  Thank you. 
 
1. In the last two weeks I have had pain in the leg (or foot) when walking …… 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
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2. In the last two weeks I have been worried that I might injure my leg …… 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
 
 
3. In the last two weeks cold feet have given me ……. 
         (tick one)  
1. A very great deal of discomfort or distress 1 
2. A great deal of discomfort or distress  2 
3. A good deal of discomfort or distress  3 
4. A moderate amount of discomfort or distress 4 
5. Some discomfort or distress   5 
6. Very little discomfort or distress   6 
7. No discomfort or distress    7 
 
 
 
 
97 
 
4. In the last two weeks, because of the poor circulation to my legs, my ability to take 
exercise or to play any sports has been ….. 
         (tick one)  
1. Totally limited, couldn’t exercise at all  1 
2. Extremely limited     2 
3. Very limited     3 
4. Moderately limited    4 
5. A little limited     5 
6. Only very slightly limited    6 
7. Not at all limited     7 
 
 
5. In the last two weeks my legs have felt tired or weak ….. 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
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6. In the last two weeks, because of the poor circulation to my legs, I have been 
restricted in spending time with my friends or relatives ….. 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
 
 
7. In the last two weeks I have had pain in the foot (or leg) after going to bed at night  
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
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8. In the last two weeks pins and needles or numbness in my leg (or foot) have caused 
me …. 
         (tick one)  
1. A very great deal of discomfort or distress 1 
2. A great deal of discomfort or distress  2 
3. A good deal of discomfort or distress  3 
4. A moderate amount of discomfort or distress 4 
5. Some discomfort or distress   5 
6. Very little discomfort or distress   6 
7. No discomfort or distress    7 
 
 
 
9. In the last two weeks the distance I can walk has improved ….. 
          (tick one) 
  1. Not at all (tick this if distance is unchanged or has decreased) 1 
  2. A little        2 
  3. Somewhat        3 
  4. Moderately        4 
  5. A good deal        5 
  6. A great deal        6 
  7. A very great deal       7 
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10. In the last two weeks, because of the poor circulation to my legs, my ability to walk 
has been  
         (tick one)  
1. Totally limited, couldn’t walk at all  1 
2. Extremely limited     2 
3. Very limited     3 
4. Moderately limited    4 
5. A little limited     5 
6. Only very slightly limited    6 
7. Not at all limited     7 
 
 
 
11. In the last two weeks being (or becoming) housebound has been a concern of mine  
         (tick one)  
1. A very great deal     1   
  
2. A great deal     2 
3. A good deal     3 
4. Moderately     4 
5. Somewhat      5 
6. A little      6 
7. Not at all      7 
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12. In the last two weeks I have been concerned about having poor circulation to my 
legs ….. 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
 
 
13. In the last two weeks I have had pain in the foot (or leg) when I am at rest ….. 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
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14. In the last two weeks, because of the poor circulation to my legs, my ability to climb 
stairs has been ….. 
         (tick one) 
1. Totally limited, couldn’t climb stairs at all 1 
2. Extremely limited     2 
3. Very limited     3 
4. Moderately limited    4 
5. A little limited     5 
6. Only very slightly limited    6 
7. Not at all limited     7 
 
 
 
 
 
15. In the last two weeks, because of the poor circulation to my legs, my ability to take 
part in social activities has been ….. 
         (tick one) 
1. Totally limited, couldn’t socialise at all  1 
2. Extremely limited     2 
3. Very limited     3 
4. Moderately limited    4 
5. A little limited     5 
6. Only very slightly limited    6 
7. Not at all limited     7 
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16. In the last two weeks, because of the poor circulation to my legs, my ability to 
perform routine household work has been ….. 
          (tick one) 
1. Totally limited, couldn’t perform housework at all 1 
2. Extremely limited      2 
3. Very limited      3 
4. Moderately limited     4 
5. A little limited      5 
6. Only very slightly limited     6 
7. Not at all limited      7 
 
 
 
 
 
17. In the last two weeks ulcers in the leg (or foot) have given me pain or distress ….. 
          (tick one) 
  1. All of the time      1 
  2. Most of the time      2 
  3. A good bit of the time     3 
  4. Some of the time      4 
  5. A little of the time      5 
  6. Hardly any of the time     6 
  7. None of the time (tick this if you do not have leg ulcers)  7 
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18. Because of poor circulation to my legs, the overall range of activities that I would 
have liked to do in the last two weeks has been ….. 
          (tick one) 
1. Severely limited – most activities not done   1 
2. Very limited       2 
3. Moderately limited – several activities not done   3 
4. Slightly limited       4 
5. Very slightly limited – very few activities not done  5 
6. Hardly limited at all      6 
7. Not limited at all – have done all the activities that I wanted to 7 
 
 
 
 
19. In the last two weeks the poor circulation to the legs have made me feel frustrated  
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
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20. In the last two weeks when I do get pain in my leg (or foot) it has given me …. 
         (tick one)  
1. A very great deal of discomfort or distress 1 
2. A great deal of discomfort or distress  2 
3. A good deal of discomfort or distress  3 
4. A moderate amount of discomfort or distress 4 
5. Some discomfort or distress   5 
6. Very little discomfort or distress   6 
7. No discomfort or distress    7 
 
 
 
 
21. In the last two weeks I have felt guilty about relying on friends or relatives ….. 
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
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22. In the last two weeks, because of the poor circulation to my legs, my ability to go 
shopping or carry bags has been ….. 
         (tick one) 
1. Totally limited, couldn’t go shopping at all 1 
2. Extremely limited     2 
3. Very limited     3 
4. Moderately limited    4 
5. A little limited     5 
6. Only very slightly limited    6 
7. Not at all limited     7 
 
 
23. In the last two weeks I have worried I might be in danger of losing a part of my leg 
or foot  
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
 
 
 
 
107 
 
24. In the last two weeks the distance I can walk has become less ….. 
 
1. A very great deal       1 
2. A great deal       2 
3. A good deal       3 
4. Moderately       4 
5. Somewhat        5 
6. A little        6 
7. Not at all – tick if distance is unchanged or has increased 7 
 
 
25. In the last two weeks I have been depressed about the poor circulation to my legs  
         (tick one) 
  1. All of the time     1 
  2. Most of the time     2 
  3. A good bit of the time    3 
  4. Some of the time     4 
  5. A little of the time     5 
  6. Hardly any of the time    6 
  7. None of the time     7 
 
THANK YOU  - this completes the Walking Impairment and Vascular Quality of Life 
Questionnaires. 
 
 
